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ABSTRACT 
Our knowledge about reactive oxygen species (ROS) and reactive nitrogen species (RNS) has been 
changed from simple damaging molecules to redox signaling mediators. ROS/RNS mediated 
signaling is mainly based on the reversible post-translational modifications of cysteine which works 
as a switch for protein functions. A proper amount of ROS/RNS is necessary to trigger such 
signaling, while excessive amount will lead to oxidative and nitrosative stress, which was recently 
defined as the disruption of redox signaling and control. In order to maintain the redox homeostasis, 
mammalian cells are equipped with two major antioxidant systems: the thioredoxin (Trx) system, 
which is composed of Trx, thioredoxin reductase (TrxR) and NADPH, and the glutaredoxin (Grx) 
system, which is grouped by Grx, glutathione (GSH), glutathione reductase (GR) and NADPH. 
Both systems play important roles in counteracting ROS/RNS and regulating redox signaling. 
In Paper I, we investigated the toxicity of several arsenic compounds on mammalian cells. We 
found that arsenical-induced cytotoxicity was related to inhibition of TrxR, suggesting an important 
role of TrxR for cell survival and potential usage as an anti-cancer target. Among the compounds, 
As6 and As7 exhibited higher cytotoxicity by directly oxidizing Trx1 and leading to the formation 
of a structural disulfide between Cys63 and Cys69. The formation of Cys63-Cys69 disulfide 
blocked the electron transfer from TrxR to peroxiredoxin (Prx) via Trx1, which allowed H2O2 to 
accumulate and activate the Nrf2 antioxidant pathway. This study highlighted the importance of the 
structural cysteines in human Trx1 and provided a potential rational design of new anticancer agents. 
In Paper II, we studied the effect of Apatone, a vitamin C and vitamin K3 combination used for 
cancer treatment, on antioxidant systems. We found that Apatone induced oxidative stress in 
various cancer cell lines which is characterized by GSH depletion, protein glutathionylation, and 
Trx1 oxidation. In addition, it inhibited ribonucleotide reductase (RNR), which is essential for DNA 
replication and repair, and caused replicative stress. A caspase-independent cell death pathway was 
also elucidated that Apatone elevated lipid peroxidation which triggered the nuclear translocation of 
apoptosis-inducing factor (AIF). We conclude that Apatone works by dramatically disturbing the 
redox balance in cancer cells. 
In Paper III, the role of nitric oxide (NO) during trypanosome infection was studied by using a 
Trypanosoma Brucei infected inducible nitric oxide synthase knocked (inos-/-) mice model. NO 
exhibited a protective role by maintaining the integrity of blood-brain-barrier (BBB). We found that 
macrophage-derived NO curbed the inflammatory effect of TNF-α by S-nitrosylating the p65 
subunit of NF-κB, a transcription factor staying in the center of inflammation. Matrix 
metalloproteinase 9 (MMP9), one of the targets of NF-κB degrading BBB, was also decreased by 
NO. Thus we conclude that NO plays a protective role during parasite infection by serving as a 
negative feedback for neuronal inflammatory signaling.  
In Paper IV, we characterized Grxs as S-denitrosylases catalyzing the reversible S-nitrosylation. 
We observed that reduced human dithiol Grx1 and Grx2a denitrosylated S-nitrosothiols (SNOs) 
directly by the active site dithiol. GSH can denitrosylate part of protein SNOs, while some of them 
are stable in the presence of high concentration of GSH. Both dithiol and monothiol Grxs exhibited 
denitrosylation ability to GSH-stable SNOs. We proposed Grxs catalyze S-denitrosylation via both 
dithiol and monothiol mechanisms. 
To summarize, this thesis consolidated the importance of Trx and Grx systems in fighting against 
ROS/RNS and mediating redox signaling in mammalian cells. 
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1 INTRODUCTION 
1.1 THE APPEARANCE OF OXYGEN ON EARTH 
We cannot survive without oxygen (O2), which constitutes 21% of the atmosphere we are 
living in now. However, when the first life-like structure appeared about 3.5 billion years ago 
[1], the atmosphere surrounding Earth was quite different. The components of atmosphere 
then were mainly reducing gases, such as hydrogen (H2), nitrogen (N2), water vapor (H2O), 
ammonia (NH3), methane (CH4) and H2S. Although the abundance of element oxygen was 
huge, it mainly existed as oxide, such as carbon oxide (CO), carbon dioxide (CO2), hydrogen 
oxide (water, H2O), as the reducing environment rapidly reduced the small amount of oxygen 
produced by ultraviolet photolysis of water vapor [2]. So we can easily speculate that O2 was 
dispensable for the first-ever life on our planet.  
Evidence showed that it was until 2.5 billion years ago that oxygen level in the atmosphere 
started rising [3]. During the 1 billion years oxygen-free gap, anaerobic metabolism was the 
only way of gaining energy for all living organisms to survive, and evolve. The turning point 
was marked around 2.7 billion years ago by the evolution of oceanic cyanobacteria, which 
utilizes H2O as the electron donor to fix CO2 for energy production and releases O2 as a by-
product, as the very simplified scheme follows: 
 
At the beginning, the ocean which was fulfilled with metals (mainly iron) in their reduced 
form trapped most of the oxygen. It took another several hundred millions of years to saturate 
the metals and finally, the concentration of O2 in the atmosphere started rising rapidly. The 
fast increase of O2 in the atmosphere was termed the Great Oxidation Event (GOE) which 
happened about 2.3 billion years ago and dramatically changed the ecology [4].  
As the Nobel laureate Albert Szent-Györgyi (1893 –1986) said, “Life is nothing but an 
electron looking for a place to rest”. Indeed, we can divide all living organisms on earth 
simply by how they manage electron flow: the photosynthetic organisms which use the solar 
light to pump electrons to a higher energy position; and the rest including us which live on 
the energy released by electrons jumping from higher energy level to lower energy level [5]. 
The electron flow is the driven force of evolution.  
In general, electrons flow to and rest in the molecule that wants them most. Each molecule of 
O2 needs four additional electrons to couple all the unpaired electrons on its spin orbitals. The 
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chemical structure of O2 makes it eager for electrons. Other reasons may also explain why O2 
is favored as a biological electron acceptor. First of all, aerobic respiration is a (19 fold!) 
more efficient way to extract energy than anaerobic metabolism; secondly, O2 can pass 
through biological membranes; lastly, the final products of aerobic respiration are H2O and 
CO2, which can be recycled by photosynthetic organisms. Being aerobic seems like a perfect 
style to live with, and indeed evolution has shown us the right choice, only if we do not have 
to pay the price -- reactive oxygen species [6]. 
1.2  REACTIVE OXYGEN SPECIES (ROS) 
From the anaerobic point of view, O2 is a toxic pollutant and the oxidative crisis expelled 
anaerobes to the places where oxygen level keeps low, such as deep ocean and lakes. It was 
until 1954 that Rebeca Gerschman and colleagues first time proposed that oxygen toxicity 
was related to free radicals and reactive oxygen species (ROS) formation [7]. Free radicals 
are molecules with one or more unpaired electrons and ROS are those radicals and reactive 
molecules derived from oxygen. During the successive reduction of O2 to H2O, different ROS 
are produced stepwise (Fig. 1). O2 receiving one electron results in superoxide anion radical 
(O2
·−
) (Fig. 1, Step 1), which sequentially takes another electron and two concomitant 
protons to generate hydrogen peroxide (H2O2) (Fig. 1, Step 2). When one more electron is 
taken by H2O2, the molecule is split into a hydroxyl anion (OH
−
) and a hydroxyl radical (HO
·
) (Fig. 1 Step 3). Hydroxyl radical is fiercely reactive with an extremely short half-life (10
-9
 
second) [8] and can take another electron and a proton to yield water [9] (Fig. 1 Step 4). ROS 
also include peroxides derived from lipids [10] and proteins[11]. ROS can also interact with 
other reactive species, for example, superoxide anion with nitric oxide (NO) to form 
peroxynitrite (Fig. 1 Step 6), which will be discussed in a later section. 
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Fig. 1 A simplified scheme of biological reduction of O2 to H2O. Most of the O2 can be reduced directly into 
H2O by a four-electron mechanism without ROS formation catalyzed by cytochrome oxidase (Step 7) [12]. A 
small part of O2 will go through successive reduction by receiving four electrons one by one and generate ROS 
(Step 1 - 4). Superoxide anion can react with NO to form peroxynitrite (Step 6).  
1.2.1 Production of ROS 
ROS can be produced by exogenous factors in the environment we live. For example, 
exposure to sunlight, both the low-energy visible light and ultraviolet (UV) light, can directly 
induce ROS production in cells [13, 14]. Not to mention the ionizing radiation such as X-ray, 
nuclear weapons with much higher energy [15]. Inhalation of air pollutant and smoking 
cigarette are also associated with increased ROS production [16, 17]. Some chemical 
compounds and toxins exert their poisonousness by inducing ROS production [18, 19]. ROS 
can be generated in our food during the storage and processing [20]. However, it is the 
endogenous ROS more biologically important because they continuously influence cells at 
every stage of their lifespan. Several main sources of ROS within cells will be discussed as 
follows. 
1.2.1.1 Mitochondria 
Mitochondria are considered as the cellular “power station”. The endosymbiotic theory for 
mitochondrial origin has been widely accepted that mitochondria were once free-living 
prokaryotes and taken up by the eukaryotic ancestor [21]. Since then, they started their 
significant roles in leading evolution and contributing every aspect of cellular events, not only 
boosting energy production but also mediating programmed cell death, forming nuclear 
capsules and endomembrane system [22]. However, mitochondria came along with a 
dangerous tool, electron transport chain (ETC) which is composed of a series of compounds, 
peptides, enzymes and protein complexes (Complex I to V), to burn the fuels.  
Electron donors from the tricarboxylic acid (TCA) cycle, such as NADH and FADH2, donate 
electrons to Complex I and Complex II, respectively [23]. As the electrons pass through the 
ETC, any leakage caught by O2 will lead to the formation of O2
·−
. The leakage mainly 
happens at Complex I and Complex III and makes them the main sources of ROS in 
mitochondria. It has been estimated that the ROS production at Complex I is about half as at 
Complex III [24]. Complex II was also reported as an O2
·− 
production site although the 
contribution is lower than Complex I [25, 26]. O2
·− 
then can be converted into H2O2 
spontaneously or catalyzed by the superoxide dismutases (SODs) (Fig.2).  
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1.2.1.2 Endoplasmic reticulum (ER) 
ER is an important organelle for protein quality control which ensures proteins are 
synthesized, folded and post-translational-modified correctly. Different from the cytosol, ER 
is a highly oxidizing environment with a high oxidized glutathione to reduced glutathione 
(GSSG/GSH) ratio which facilitates disulfide bonds formation during protein maturation. 
During the process, electrons can be transferred from unfolded proteins to protein disulfide 
isomerase (PDI), then to endoplasmic reticulum oxidoreductin-1 (ERO-1) and finally to O2 to 
produce H2O2 [27] (Fig.2). Several members of quiescin sulfhydryl oxidase (QSOX) family 
in ER were also found to generate H2O2 [28]. It has been estimated that ER accounts for 
about 25% of ROS production in growing cells [29]. 
1.2.1.3 Peroxisome 
The peroxisome is another membrane-capsuled organelle playing multiple roles in both 
anabolic and catabolic reactions. Peroxisomes are responsible for oxidative breakdown some 
metabolites such as fatty acids, purines and amino acid therefore they contain different 
oxidases, including Acyl-CoA oxidases, urate oxidase, D-amino acid oxidase, D-aspartate 
oxidase, L-pipecolic acid oxidase, L-α-hydroxyacid oxidase, polyamine oxidase, and 
xanthine oxidase, which extract electron from substrates and pass it to O2 to produce H2O2 as 
their normal function [30]. So peroxisome has been considered as another main source of 
ROS in cells, especially the tissues with high metabolic efficiency and it is estimated that 
peroxisome accounted for 35% of all H2O2 produced in rat liver [31].  
1.2.1.4 NADPH Oxidase (NOX) 
The sources we discussed above generate ROS as a by-product, but NOXs are “professional” 
ROS producers [32]. So far, seven members of NOX family have been identified in various 
mammalian tissues, namely, Nox1-5 and DUOX1-2 (dual oxidase 1 and 2). All NOX family 
members are membrane-bound proteins which transfer electrons from NADPH to O2 and 
yield O2
·−
 (Fig.2). ROS produced by NOXs were primarily found as a weapon used by host 
phagocytes to kill microorganisms. Later studies revealed that NOXs produced ROS are also 
involved in other cellular events such as cellular signaling, gene expression, oxygen sensing 
and so on [33].  
1.2.1.5 Metal-induced ROS Production 
Transition metal ions are key elements for some proteins which are indispensable for cellular 
processes. Due to their electron distribution, transition metal ions can easily undergo one-
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electron redox reaction and produce reactive species [34]. This property renders them the 
capacity to generate highly reactive hydroxyl radicals (HO
·
) from H2O2 by Fenton reaction:  
 
where M
n+
 is a transition metal ion. Iron was the first metal found by Fenton to catalyze the 
reaction, later copper, chromium, cobalt and certain other metals were also found as Fenton's 
reagents in vivo [35].  
1.3 REACTIVE NITROGEN SPECIES (RNS) 
RNS refer nitric oxide and those reactive molecules derived from nitric oxide (NO). Similar 
to ROS, RNS have been found to take part in various biological processes in cells. NO also 
react with ROS to produce highly reactive radicals, such as peroxynitrite, which may cause 
damage to cellular components and contribute to pathological conditions. The thesis will 
mainly focus on NO since it is the precursor of all RNS. 
1.3.1 Production of NO 
Nitric oxide (NO) is a simple diatomic molecule which was considered as an air pollutant 
first, then surprisingly found to play diverse biological roles in living organisms. In 1977, 
Murad’s group discovered that NO and other NO donors increased the guanylate cyclase’s 
activity, therefore may influence smooth muscle relaxation [36]. In 1980, Furchgott and 
colleagues found that endothelium can release a substance, endothelium-derived relaxing 
factor (EDRF), which leads to vasodilation [37]. A further study performed by Ignarro 
demonstrated the EDRF turned out to be nitric oxide due to their identical properties [38]. 
Nobel Prize was awarded to these three scientists who contributed a lot to discover the 
physiological roles of NO in 1998.  
1.3.1.1 Nitric oxide synthase (NOS) 
NO can be synthesized endogenously by nitric oxide synthases (NOSs) which convert L-
arginine and O2 into NO and L-citrulline via a complex redox reaction in the presence of the 
cofactors: NADPH, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and 
tetrahydrobiopterin (BH4) [39]. There are three NOS isoforms identified in human bodies and 
named mainly depending on the tissue distribution, respectively, neuronal NOS (nNOS), 
endothelial NOS (eNOS) and inducible NOS (iNOS). 
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nNOS was first found in central and peripheral nervous system. It has been also found in 
other tissues such as skeletal muscle [40], cardiac myocytes [41], and vascular smooth muscle 
cells [42]. eNOS is mainly expressed in endothelial cells in blood vessels, but also present in 
platelets, smooth muscle cells, hepatocytes and certain types of neuronal cells [43]. Both 
nNOS and eNOS are constitutively expressed and their activity is dependent on Ca
2+
 fluxes 
that enable the binding of calmodulin [43]. Different from the other two isoforms, iNOS is 
regulated in a Ca
2+
-calmodulin-independent manner and not constitutively expressed in cells. 
Instead, the expression and activity of iNOS can be induced dramatically by inflammatory 
stimulations such as cytokines and lipopolysaccharide (LPS). The property of iNOS is used 
by immune cells like macrophages [44], natural killer (NK) cells [45] and neutrophils [46] to 
fight against invading microbes and tumor cells [47]. 
1.3.1.2 The nitrate-nitrite-nitric oxide pathway 
An alternative source of NO is the nitrate (NO3
-
) – nitrate (NO2
-
) – NO pathway [48]. Dietary 
uptake of leafy vegetables (e.g. spinach and lettuce) and beetroot is the major source of 
inorganic nitrate [49]. Nitrite is found at relatively low level in natural products; however it is 
commonly used as an additive of preserved food [50]. In order to be used as a NO donor, 
nitrate needs to be reduced to nitrite by digestive track bacteria [51] or mammalian nitrate 
reductase [52]. The liberation of NO from nitrite is catalyzed by several molecules, including 
xanthine oxidoreductase [53], ascorbate [54], hemoglobin [55], carbonic anhydrase [56], 
aldehyde oxidase [57], and enzymes in the mitochondrial respiratory chain [58]. Different 
from NOSs, NO derived from nitrate and nitrite does not require oxygen so it is believed that 
nitrate – nitrite – NO pathway can ensure the NO supply under hypoxic conditions [59]. On 
the other hand, NO can be oxidized into nitrite and nitrate in the presence of oxygen or metals 
under different conditions [60].  
1.3.2 Peroxynitrite (ONOO-) 
Generally, NO is not too active and can be well-tolerated by cells. For example, NO is used 
by brain as a neurotransmitter without any toxicity during a healthy person’s life span. 
However, under pathological conditions, such as cerebral ischemia, the same molecule can 
become highly damaging [61]. The paradox was explained by ONOO
-
, a strong oxidizing and 
nitrating agent which is formed by the reaction of NO and O2
·−
 (Fig.1, step 6) and capable of 
causing damage to protein, lipid, and DNA. The reaction between NO and O2
·−
 is fast, with 
an estimated rate constant of 6.7 × 10
9 
M
−1
· s
−1
 [62] and NO is one of the only few biological 
molecules which reacts faster with O2
·−
 than superoxide dismutase (SOD) (estimated rate 
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constant of  2× 10
9 
M
−1
· s
−1
) [63]. However, considering the concentration of SOD is much 
higher than NO and it keeps O2
·−
 at a relatively low level normally, a large amount of 
peroxynitrite can only be formed when a huge amount of NO and O2
·−
 was produced at the 
same time, such as inflammation. Surprisingly, as an anion, peroxynitrite is relatively stable 
in the aqueous solution not only because it can fold into a cis-conformation and distribute the 
negative charge all over the ring structure [64], but also form hydrogen bonds with water 
[65]. The stability contributes a lot to the toxicity of peroxynitrite because it can travel to a 
further spot.  
 
Fig. 2 Production of ROS and RNS in cells. ROS are produced via the leaking of electrons from the 
mitochondrial respiration chain, or through NOX under physiological conditions. ER and peroxisome also 
contribute to cellular ROS production. NO can be synthesized by NOS or the nitrate-nitrite pathway. NO and  
O2
·- form peroxynitrite. SOD can convert O2
·- into H2O2 which goes through Fenton’s reaction to yield HO
·
. 
1.4 PHYSIOLOGICAL ROLE OF ROS AND RNS 
ROS and RNS are important molecules in many physiological processes. The reactivity is the 
foundation for their functions in that it renders them the possibility to interact with other 
molecules. The physiological role of ROS and RNS can be divided into two aspects: the 
killing and the signaling effect. 
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1.4.1 The killing effect of ROS and RNS 
Our immune system has developed many strategies to keep us from infections caused by 
pathogenic microbes. The main weapon used is ROS and RNS, which can cause damage to 
microbial components, such as lipid, DNA, and proteins. It was firstly reported by Babior et 
al in 1973 that professional phagocytes, mainly macrophages, and neutrophils, produced a 
large amount of ROS, known as “respiratory burst” or “oxidative burst” by NOX during 
bacterial infection [66]. Since then the role of ROS in the immune system has been 
intensively studied. NO production is also a feature of some immune cells such as 
macrophages, microglia, neutrophils, dendritic cells (DC), NK cells [67]. Although NO itself 
is not highly toxic, it forms peroxynitrite with O2
·-
 produced by NOX. The anti-microbial 
effect of ROS and RNS has been demonstrated by various studies showing a broad killing 
spectrum of microbes ranging from virus to parasites [68]. However, the role of ROS/RNS is 
far beyond as a weapon, they are also important modulators for immune cell differentiation 
and activation, cytokine secretion and so on. 
1.4.2 The Signaling Effect of ROS and RNS 
For many years, ROS and RNS were considered as undesired toxic metabolites mainly 
causing damages. Surprisingly, during last few decades, they were re-recognized as 
messenger molecules mediating the redox signaling. A large part of ROS/RNS-mediated 
signal transduction relies on the post-translational modification (PTM) of cysteine thiol (-SH) 
within proteins. Several properties qualify thiols as signal switches. First of all, thiols are 
susceptible to ROS/RNS challenge that lays a foundation for its sensitivity. Secondly, due to 
the different local environment, thiols exhibit different reactivity which renders them 
selectivity [69]. Lastly, most of the thiol modifications are reversible which provides 
flexibility for sophisticated signaling regulation.  
The major redox signaling molecules in cells are H2O2 and NO. H2O2 can lead to reversible 
thiol modifications such as S-sulfenylation (sulfenic acid, -SOH), sulfinic acid (-SO2H), 
disulfide bond (-S-S-), and S-glutathionylation (-SSG) when glutathione (GSH) is around. If 
sulfinic acid gets further oxidized, sulfonic acid (-SO3H), an irreversible thiol modification, 
will be formed and it has been considered as a hallmark of diseases and usually leads to 
permanent functional inactivation and protein degradation [70]. NO can manipulate the 
formation of S-nitrosylation (-SNO), which is also reversible. Peroxynitrite is versatile thiol 
modifier that has shown the ability to form –SOH, -SO2H, -SO3H, -SNO, -S-S- [71] and –
SSG [72].  
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1.4.2.1 Sulfenic Acid and Sulfinic Acid 
For many thiols, the first step of oxidation by H2O2 is sulfenic acid (Fig.3 step 1). Sulfenic 
acid is not stable and rapidly forms intramolecular or intermolecular disulfides with another 
thiol (Fig.3 step 7). Disulfide bonds are relatively inactive thus they can stabilize the 
structure of proteins and prevent them from further oxidation. Sulfenic acid also reacts with 
GSH to yield S-glutathionylation (Fig.3 step 4) [73]. However, when the microenvironment 
is suitable, sulfenic acid can be stabilized. The redox regulation of protein tyrosine kinases 
(PTPs) is a well-studied example of sulfenic acid mediated signaling. During ligand-receptor 
based signal transduction, the catalytic cysteine in PTPs can be oxidized by H2O2 produced 
by NOX into sulfenic acid, which inhibits PTPs activity and activates protein tyrosine kinases 
(PTKs) to phosphorylate target proteins [74]. 
The instability of sulfenic acid, on the other hand, makes it vulnerable to further oxidation 
that leads to sulfinic (Fig.3 step 2) and sulfonic acid (Fig.3 step 3). The sulfinic acid 
modification has been found in several proteins such as peroxiredoxins (Prxs) [75], SOD1 
[76] and matrix metalloproteases (MMPs) [77]. 
1.4.2.2 Disulfide Bonds 
Disulfide bonds can be formed by further oxidizing intermedia modifications such as sulfenic 
acid (Fig.3 step 7), S-glutathionylation (Fig.3 step 8), and S-nitrosylation. They can also be 
produced by direct attack of hydroxyl radical from Fenton reaction [78]. Disulfide bonds also 
participate cellular signaling. For example, cell-surface tissue factor (TF) is important to 
activate coagulation and signaling relevant to inflammation and angiogenesis [79]. It has been 
reported that disulfide formation between Cys186 and Cys209 in TF is required for 
coagulation activation [80]. PTEN (phosphatase and tensin homolog), for instance, an tumor 
suppressor essential for regulating signaling pathways involved in apoptosis was shown to be 
inactivated when cells were exposed to H2O2 due to the formation of an intramolecular 
disulfide bond between Cys124 and Cys71 [81].  
1.4.2.3 S-glutathionylation 
GSH is the dominant low-molecular-weight antioxidant in mammalian cells. The ratio 
between GSH and GSSG maintains the cellular redox potential and contributes significantly 
to redox balance. When the balance is disrupted, decreased GSH/GSSG ratio can cause 
mixed disulfide formation between reactive thiols and GSH, named S-glutathionylation 
(Fig.3 step 4), which is considered as a protection of thiols from irreversible oxidation [82]. 
Under basal condition, protein S-glutathionylation is a well-controlled, reversible PTM and 
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plays a role in redox signaling. For example, Ca
2+
 dependent phosphorylation of ERK and 
cAMP/Ca
2+
 response element binding protein (CREB) is required for synaptic plasticity. A 
study found that H2O2 could cause increased glutathionylation and activation of ryanodine 
receptors (RyR), which release Ca2+ and enhance ERK and CREB phosphorylation and 
helped maintain the long-term potentiation (LTP) in the hippocampus [83]. S-
glutathionylation of PTP1B was detected in conditions when GSH/GSSG ratio drops or in the 
presence of H2O2, suggesting it takes part in the regulation of ligand-receptor based signal 
transduction [84]. 
1.4.2.4 S-nitrosylation 
The first characterized physiological signaling of NO in mammals is binding to the heme 
domain of soluble guanylate cyclase (sGC) and activates its activity to convert GTP to 
cGMP, which triggers downstream cascades involving in vasodilation, smooth muscle 
relaxation and neurotransmission [85]. In addition to the classical signaling pathway 
mentioned above, NO is involved in a PTM named S-nitrosylation which is defined as 
directly adducting the NO moiety to a reactive thiol of cysteine to form S-nitrosothiol (SNO). 
Similar with other PTMs such as phosphorylation, S-nitrosylation alters proteins activities, 
interactions pattern and redox status [86]. Growing number of proteins have been reported to 
be S-nitrosylated in different biological contexts. Interestingly, S-nitrosylation does not occur 
randomly, it shows certain specificity. Factors like NO donor type, thiol reactivity, and 
cellular local redox environment contribute to the selectivity of S-nitrosylation [87]. 
Several transcription factors are regulated by S-nitrosylation. For example, NF-κB plays a 
central role in immune system. Both p50 [88] and p65 [89] subunits of NF-κB were found to 
be S-nitrosylated at a cysteine in the DNA-binding region by iNOS-derived NO with a 
hampered binding ability during immune response. The observation indicated that NF-κB is 
negatively regulated by NO. Hypoxia-inducible factor 1 (HIF-1) is a master transcriptional 
factor mediating the hypoxic adaptation which is essential for cellular survival. S-
nitrosylating cysteines in HIF-1α not only promoted its DNA binding [90], but also kept it 
from proteasomal degradation [91].  
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Fig.3 Post-translational modification of cysteines by ROS and RNS. A free thiol (-SH) can be firstly oxidized 
by H2O2 to sulfenic acid (-SOH) (Step 1), then to sulfinic acid (-SO2H) (Step 2), both are reversible. Further 
oxidation from –SO2H to –SO3H makes the modification irreversible (Step 3). Nitric oxide can lead to S-
nitrosylation (-SNO) (Step 5), which is not stable and easily converted into S-glutathionylation (-SSG) (Step 6). 
–SSG can also be formed via GSH/GSSG reacting with thiols (Step 4). Disulfide (-S-S-) is also stable 
modification derived from –SSG or –SOH (Step 7 and Step 8) 
1.5 OXIDATIVE AND NITROSATIVE STRESS 
If we consider ROS and RNS as the weapons used fighting against invading microbial 
enemies, we should notice that friendly fire is unavoidable as it happens in every war. In our 
scenario, the killing effect of ROS and RNS will not only be cast on the alien intruders, but 
also cells constituting our bodies. Luckily, mammalian cells are equipped with anti-oxidant 
mechanisms, both enzymatically and non-enzymatically, to counteract the deleterious effects 
of ROS and RNS. Under physiological condition, the production and disposal of ROS/RNS 
are maintained in an equilibrium state, so-called redox balance or redox homeostasis. 
However, when production of ROS/RNS exceeds the ability of disposal by anti-oxidant 
systems, the balance collapses and oxidative/nitrosative stress is induced [92]. With increased 
knowledge about redox signaling, the concept of oxidative and nitrosative stress has evolved 
during last two decades and it is preferably considered as the disruption of a proper redox 
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signaling and control [93]. Indeed, oxidative and nitrosative stress induced cellular damage 
and signal dysregulation have been considered as hallmarks of various diseases. 
1.5.1 Cellular Damage 
Excessive ROS/RNS react directly with biological molecules such as lipid, DNA, and 
proteins and cause damages to them. For example, biological membranes contain 
polyunsaturated fatty acid to maintain their functions and fluidity [94]. However, unsaturated 
lipid is sensitive to ROS/RNS which produces lipid peroxides, disrupts normal membrane 
structure of cells and organelles, such as mitochondria and ER, and results in loss of function 
and enveloped contents, finally necrotic cell death [95]. Both nuclear and mitochondrial DNA 
can be attacked by ROS/RNS and several types of DNA lesion have been observed including 
oxidation of sugar and base, DNA single strand break [96] and double strand break [97] 
which will trigger apoptosis [98].  
1.5.2 Signaling Dysfunction  
The redox signaling is also affected by oxidative and nitrosative stress and the dysfunction is 
reflected in aberrant protein thiol modifications. For example, chronic inflammation is 
characterized by persistent activation of macrophages which results in continuous ROS/RNS 
production. Due to the DNA-damage effect of ROS/RNS, chronic inflammation has been 
considered as one of the risk factors for tumor initiation [99]. Usually, when DNA damage 
happens, the genome guardian, p53 gets activated as a transcription factor and triggers 
multiple downstream effects, such as DNA repair, cell cycle arrest, and apoptosis so cells 
with damaged DNA will not transform into cancer cells [100]. Due to the high level of 
ROS/RNS under inflammation, cysteine residues in the DNA binding site of p53 can be 
abnormally S-nitrosylated [101] or S-glutathionylated [102]. The redox modification of p53 
leads to the loss of surveillance function. 
In contrast to cancer in which cells stop dying, neurodegenerative diseases suffer from 
undesired neuron death caused by oxidative/nitrosative stress. Caspase - mediated neuronal 
cell death contributes to the pathological progress of neurodegenerative diseases. The X-
linked inhibitor of apoptosis protein (XIAP), an E3 ligase, binds to several members of 
caspase family directly and mediates their degradation, therefore plays a protective role in 
neurodegenerative diseases [103]. In Parkinson’s Diseases (PD), XIAP was found to be S-
nitrosylated and lose its binding ability to caspases, which was thus stabilized and triggered 
the apoptosis cascade [104]. S-nitrosylation cysteine 150 of GAPDH promoted its binding to 
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Siah1 and enhanced the GAPDH-Siah1 complex's nuclear translocation, which initiated the 
apoptotic pathway contributing to neuronal death [105].  
1.6 ANTIOXIDANT SYSTEMS 
In order to maintain the redox balance, mammalian cells are equipped with antioxidant 
systems to neutralize ROS/RNS or repair the caused damages. Moreover, antioxidant systems 
widely affect redox signaling by reversible cysteine modifications.  
1.6.1 Small Antioxidant Molecules 
Small antioxidant molecules directly scavenge ROS/RNS via non-enzymatic mechanisms. 
Some of them are endogenously synthesized while others can be only obtained by dietary 
uptake.  
Glutathione (GSH) is the most abundant low molecular antioxidant in eukaryotes with an 
estimated concentration at the millimolar level and most of them are in reduced form [106]. 
The tripeptide Glu-Cys-Gly (γ-glutamyl-cysteinyl-glycine) is synthesized endogenously in a 
two-step process. The first step is to link a cysteine and a glutamate to form γ-
glutamylcysteine which is carried out by the glutamate cysteine ligase (GCL). The second 
step, catalyzed by GSH synthetase, is to add a glycine to the γ-glutamylcysteine. The first 
step is considered as the rate-limiting step in GSH synthesis [107]. Although GSH is 
exclusively synthesized in the cytosol, it is distributed all over the cells and organelles, such 
as ER (where GSSG is the dominant form [108]), nucleus and mitochondria [109]. The ratio 
of GSH to its oxidized form, GSSG, (GSH: GSSG) determines the redox status of cells and 
has been used a biomarker for oxidative stress [110]. GSH not only reacts directly with 
oxidizing agents to detoxify them, but also serves as electron donors for other efficient 
antioxidant enzymes, such as glutaredoxins, glutathione transferases, and glutathione 
peroxidases [111]. 
Exogenous small antioxidant molecules are mainly vitamins and minerals from daily food. 
Vitamin C (ascorbic acid), for example, is a water-soluble antioxidant with multiple 
biological functions. It can not only react readily with ROS/RNS but also regenerate vitamin 
E (α-tocopherols), an important lipid-soluble antioxidant protecting polyunsaturated fatty 
acids in membranes and lipoproteins from oxidative damage [112]. In addition, carotenoids 
[113], lipoic acid [114], ubiquinol [115], flavonoids [116], uric acid [117] and mineral 
supplement such as selenium [118], zinc [119] are also small antioxidant molecules 
participating the scavenging of ROS/RNS.  
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1.6.2 Antioxidant Enzymes 
The antioxidant enzymes can metabolize ROS/RNS in a more efficient and specific way than 
small antioxidant molecules. A large part of antioxidant enzymes is transcriptionally 
controlled by the Keap1/Nrf2 pathway that stays in the center of stress response. The nuclear 
factor E2-related factor 2 (Nrf2) is a transcription factor targeting genes involved in response 
to oxidative/nitrosative stress. Nrf2 is mainly regulated by a cytoplasmic protein Kelch-like 
ECH-associated protein 1 (Keap1) which is an E3 ubiquitin ligase. Under basal conditions, 
Nrf2 has a relatively short half-life and binds to Keap1 which mediates the ubiquitination and 
degradation of Nrf2 [120]. Keap1 is rich in cysteines and some of these cysteines serve redox 
sensors. In the presence of electrophilic or oxidative/nitrosative insulting, these cysteines get 
modified and Nrf2 is released from Keap1 and stabilized [121]. Then, Nrf2 translocates from 
cytoplasm into nuclei and binds the antioxidant response element (ARE) to activate the 
transcription of target genes [122], such as superoxide dismutases (SODs), catalase and 
members in thioredoxin and glutaredoxin systems. 
Superoxide dismutases (SODs) are a group of metal-containing enzymes that catalyze the 
dismutation of superoxide anion to hydrogen peroxide and molecular oxygen (Fig. 4). There 
are three isoforms of SOD in human cells, the copper and zinc-containing cytosolic SOD 
(Cu/ZnSOD, SOD1), the manganese-containing mitochondrial SOD (MnSOD, SOD2) and 
extracellular Cu/ZnSOD (SOD3) [123]. SODs are efficient to dismutate superoxide with an 
estimated rate constant of 2× 10
9 
M
−1
· s
−1
 [63]. The importance of SODs has been proven by 
genetically modified animal models lacking SODs which exhibit various abnormality such as 
hypersensitivity to ROS/RNS, neonatal or perinatal lethality [124]. 
Catalase (CAT), a heme-containing enzyme ubiquitously expressed in mammalian cells, 
catalyzes the decomposition of H2O2 to water and O2 (Fig. 4), therefore it plays a critical role 
in antioxidant defense and redox signaling. The genetic deficiency of CAT in human is called 
acatalasemia which may be related to high risk of various diseases during aging [125].  
Different from SODs and CAT, the thioredoxin and glutaredoxin systems serve not only as 
antioxidant systems but also important mediators that modulate redox signaling involved in 
numerous biological events. 
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Fig. 4 The antioxidant system in mammalian cells. SOD catalyzes the dismutation of superoxide to 
hydrogen peroxide. Small antioxidants like VC, VE can scavenge H2O2 via non-enzymatic mechanisms. 
Catalase decomposes H2O2 to H2O. Both Trx and Grx system use NADPH as the ultimate electron donor. For 
Trx system, electrons go from NADPH to TrxR to Trx to Prx, respectively. For Grx system, electrons are 
transferred from NADPH to GR to GSH to GPx, respectively. Prx and GPx are efficiently enzymes to remove 
H2O2 
1.7 THIOREDOXIN SYSTEM 
The thioredoxin system, which contains thioredoxin (Trx), thioredoxin reductase (TrxR), and 
NADPH, is the major disulfide reduction system targeting a broad range of substrates. After 
reducing its targets, a disulfide is formed in Trx that will be reduced by TrxR using NADPH 
as the electron donor (Fig.4).  
1.7.1 Thioredoxin 
Thioredoxin is a ubiquitous small enzyme around 12-kDa with a -CGPC- motif at the active 
site, which was originally found in Escherichia coli (E. coli) to provide electrons for 
ribonucleotide reductase (RNR) [126, 127]. The 3D structure of bacterial Trx was first 
described by Prof. Holmgren in 1975 [128] and now many Trxs have been structurally 
resolved [129]. The structure of Trx is known as the Trx fold, containing four β-strands in the 
core, and some α-helices surrounding the central β-sheets [130] (Fig.5). In mammalian cells, 
there are three isoforms of Trxs, Trx1 in the cytosol, Trx2 in mitochondria [131], and a testis-
specific Trx [132]. Trxs utilize the two cysteines at the active site to perform substrate 
reduction. The N-terminal cysteine at the active site first attacks the disulfide in substrate 
proteins and forms an intermedia disulfide between Trx and substrate, then the C-terminal 
 16 
cysteine at the active site takes over and leaves reduced protein and an active-site disulfide in 
Trx which can be sequentially reduced by TrxR [133]. 
Besides the two active site cysteines (Cys32 and Cys35), human Trx1 (hTrx1) contains three 
structural cysteines, Cys62, Cys69 and Cys73, issuing hTrx1 unique biological properties. 
Several studies has shown that the structural cysteines of hTrx1 can be redox-modified and 
regulated in different redox contexts [134].  
1.7.2 Thioredoxin Reductase  
Thioredoxin reductase (TrxR) is the enzyme recycling oxidized Trx to its reduced form by 
using NADPH as electron donors. Corresponding to Trxs, there are three forms of 
mammalian TrxRs, cytosolic TrxR1, mitochondrial TrxR2, and testis-specific TrxR3 (or 
TGR standing for thioredoxin and GSSG reductase due to its ability to reduce both Trx and 
GSSG) [135, 136]. Mammalian TrxRs are homodimeric flavoproteins with a molecular 
weight around 115 kDa. Each subunit contains an active site motif -CVNVGC- in its N-
terminus and a 16 amino-acid residue extension with a selenocysteine (Sec, U) in a -GCUC- 
active site motif in C-terminus [137]. Sec is the analog of cysteine in which the sulfur is 
substituted by selenium. Due to the chemical property of selenium and the high redox 
reactivity of Sec, selenoprotein TrxR is efficient in catalyzing redox reactions [138]. During 
the reduction of Trx, both subunits arranged in a head-to-tail fashion are required. Firstly, 
NADPH passes electrons to the enzyme-bound FAD in one subunit, then FAD subsequently 
transfers reducing equivalents to the -CVNVGC- active site motif of the same subunit and 
reduces the disulfide into a dithiol motif. Secondly, the dithiol-containing active site in TrxR 
reduces the C-terminal selenenylsulfide motif of the other subunit in the dimer into a 
selenolthiol motif. In turn, the selenolthiol motif reduces the substrates of TrxR, including not 
only the active site disulfide in Trx (Fig.5), but also glutaredoxin 2, PDI, Trx-like-1, 
granulysin, and some nonprotein substrates such as selenite, dehydroascorbate, lipoic acid, 
ubiquinone, cytochrome C, or the cancer drugs motexafin gadolinium and alloxan [139]. 
Knocking out TrxR1 [140] or TrxR2 [141] in mice led to early embryonic death with 
improper development, suggesting important roles of TrxRs in neonatal development. 
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Fig 5. Catalytic mechanism of mammalian TrxR and 3D structure of hTrx1 [142]. Mammalian TrxR is a 
homodimer. During the catalysis, NADPH binds to the FAD domain of TrxR and electrons are transferred from 
NADPH to N-terminal redox center where the reduction of the other subunit’s selenium-containing C-terminal 
active site. Then the reduced seleno-active site reduces the active-site-oxidized hTrx1 to its fully reduced form. 
1.7.3 Trx Targeted Proteins 
Trx interacts with a broad range of proteins not only to maintain the reducing cellular 
environment by transferring electrons to them, but also to mediate different cellular signaling 
pathways by regulating cysteine PTMs. With the help of proteomic technology, more and 
more potential targets for Trx system have been discovered [143].  
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1.7.3.1 Ribonucleotide Reductases (RNR)   
Trx was originally discovered as the electron donor to reduce RNR, the rate-limiting enzyme 
converting ribonucleotides to deoxyribonucleotides for DNA synthesis and repair [144]. 
Mammalian RNR is a α2β2 tetramer in which α2 homodimer forms R1 subunit and β2 
homodimer forms R2 subunit. Both R1 and R2 are predominantly expressed during S phase 
when a large amount of dNTP is needed [145]. R1 remains stable during cell cycle due to its 
long halftime [146] while R2 is degraded rapidly when cells exit S phase [147]. There is 
another isoform of R2, p53R2, which is induced by p53 upon DNA damage in resting cells to 
provide dNTP for DNA repair, in particular mitochondrial DNA replication and repair [148]. 
In each R2 subunit, there is a Fe-O-Fe center generating and stabilizing a tyrosyl radical, 
which can be sequentially transferred to the active site cysteine in R1 subunit to generate a 
thiyl radical which is critical for the conversion of substrates. After each cycle of reaction, a 
disulfide is formed at the active site in R1 subunit. However, due to the protein conformation, 
the active site is too narrow to be reduced directly by antioxidant enzymes. Instead, the 
reduction of the active site disulfide is performed by a pair of shuttle cysteine residues in the 
C-terminal mobile tail of R1 subunit which can be accessed and reduced by Trx and 
glutaredoxin [149]. Considering the importance of RNR for proliferating cells, it has been 
used as a drug target for cancer treatment [150]. 
1.7.3.2 Peroxiredoxins (Prxs) 
Prxs are ubiquitous enzymes efficiently catalyzing the decomposition of H2O2, lipid 
peroxides, and peroxynitrite. To date, 6 mammalian Prx isoforms have been discovered, 
namely Prx I to Prx VI which can be divided into 3 groups based on their structure and 
catalytic mechanism: 2-Cys (Prx I–IV), atypical 2-Cys (Prx V), and 1-Cys (PrxVI) Prxs. All 
isoforms contain the N-terminal cysteine which can be oxidized by their substrates rapidly 
and selectively during catalysis [151]. Usually, the N-terminal thiolate is oxidized by 
substrate into a sulfenic acid, then the other cysteine at C-terminus resolves and forms an 
intermolecular (Prx I- IV) or intramolecular (Prx V) disulfide which can be reduced by Trxs 
[152]. Prx VI, the 1-Cys Prx, is lack of the resolving cysteine, therefore, it does not form 
disulfide and cannot be reduced by Trx. Instead, the oxidized cysteine in Prx VI is reduced by 
GSH catalyzed S-transferase isoform π (GSTπ) [153]. Prxs are efficient peroxidases with an 
estimated rate constant of 10
7
 – 108 M-1 s-1 [154]. Paradoxically, a study found that human 
Prx1 can be inactivated by as little as 100 µM H2O2 and this inactivation was shown to be due 
to the hyperoxidation of the N-terminal cysteine into a sulfinic acid which cannot be 
regenerated by Trx [155]. This inactivation is called “floodgate model” which is important 
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for redox signaling since it allows non-stress H2O2 produced by NOX get stabilized and exert 
its function [151]. The sulfinic acid in Prxs can be reduced specifically by sulfiredoxin (Srx) 
[156]. Other PTMs can also modulate the activity of Prxs, such as phosphorylation [157], S-
glutathionylation [158] and S-nitrosylation [159]. Interestingly, Prx takes part in the redox 
regulation of Trx1, too. When the active site cysteine of Trx1 is oxidized, Prx can promote 
the formation of another disulfide between Cys62 and Cys69 in the presence of H2O2 [160] 
(Fig.7) 
1.7.3.3 Methionine Sulfoxide Reductase (Msr)  
Another sulfur-containing amino acid, methionine, is also sensitive to oxidation. Both free 
methionine and methionine in proteins can be oxidized by ROS to methionine sulfoxide. 
Similar to cysteine modification, methionine oxidation affects protein structure and functions 
[161]. Msrs are the enzymes catalyzing the reduction of methionine sulfoxide. Although 
different isoforms of Msrs employ different mechanisms [162], they all receive electrons 
from Trx system [163].  
1.7.4 Trx Binding Proteins 
1.7.4.1 Apoptosis-regulating Kinase 1 (ASK1)  
Trx1 has been found as a physiological inhibitor of ASK1 by direct protein-protein 
interaction (Fig.7). ASK1 is a MAP3K (Mitogen-activated protein kinase kinase kinases) 
activating MAP2K-JNK/p38 signaling cascades which are essential for ER stress-induced 
apoptosis [164]. Trx1 binds ASK1 via disulfide formation between its active site Cys32 or 
Cys35 and Cys250 in the N-terminal portion of ASK1, and inhibits ASK1 kinase activity. 
The binding also promotes the degradation of ASK1 by ubiquitin proteasome [165]. When 
cytosolic Trx1 gets oxidized in response to pro-inflammatory stimuli, ROS, or cellular stress, 
ASK1 is released from the Trx1-ASK1 complex and subsequent ASK1 dependent apoptotic 
pathway will be activated. Trx2 associates with mitochondrial located ASK1 via binding 
Cys30 within ASK1 and activates a JNK-independent apoptosis pathway [166].  
1.7.4.2 Thioredoxin Interacting Protein (TXNIP)  
The activity of Trx is also regulated by TXNIP, its endogenous inhibitor which binds to 
reduced Trx but not the oxidized form [167] (Fig.7). The interaction between Trx and TXNIP 
involves the disulfide formation between Cys32 in Trx and Cys247 in TXNIP [168]. The 
inhibitory effect of TXNIP on Trx can be achieved by two aspects: first, TXNIP competes 
with other Trx-binding proteins and release them from the Trx binding complex, i.e. ASK1 
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[169]; second, because one of the active site cysteine of Trx is involved in TXNIP binding, it 
blocks electron transfer from Trx to target proteins and leads to ROS accumulation in cells 
[170]. Collectively, TXNIP has been considered as a pro-apoptotic protein and tumor 
suppressor.  
1.7.4.3 Phosphatase and Tensin Homolog (PTEN)  
PTEN, one of the most commonly mutated tumor suppressors in human malignancies, serves 
as a phosphatase to counteract the phosphoinositide 3-kinase (PI3K)/AKT/ mammalian target 
of rapamycin (mTOR) pathway [171]. AKT-mediated activation of mTOR is involved in 
multiple processes to promote cellular proliferation and survival, such as ribosome biogenesis, 
nutrient import, growth factor response, hypoxia adaptation and so on [172]. Trx1 can bind 
PTEN directly and inhibit its phosphatase activity by forming a disulfide between Cys32 of 
Trx1 and Cys212 of PTEN [173]. On the other hand, PTEN can be indirectly regulated by 
TXNIP which binds to Trx and frees PTEN from Trx-binding for its function [174]. 
1.7.5 Trx System-mediated Redox Signaling 
Trx system mediates redox signaling via different mechanisms. Firstly, it puts out ROS/RNS 
directly before they reach target proteins. For example, Trx1 coupled Prx I/II and Trx2 
coupled Prx III/V in mitochondria can scavenge H2O2, peroxides and peroxynitrite efficiently 
[175]. Secondly, it directly binds signaling molecules and regulates their downstream events, 
such as ASK1, PTEN we discussed above. Thirdly, it modulates the redox properties of 
signaling molecules to switch on/off signaling pathways. Several important transcription 
factors are regulated by Trx system.  
1.7.5.1 Keap1/Nrf2 Pathway  
Trx system and Keap1/Nrf2 regulate each other putatively. Upon oxidative/nitrosative stress, 
Nrf2 is released from Keap1, binds to ARE and starts the transcription of antioxidant proteins 
including Trx and TrxR [122] which at the same time serves as a negative feedback to restore 
the Keap1/Nrf2 binding. Pharmaceutical inhibition or genetic depletion of TrxR usually leads 
to activation of Nrf2 [176] [177]. Nrf2 is also redox sensitive and has at least two key 
cysteines within its nuclear localization signal (NLS) and nuclear export signal (NES) 
regions. Oxidation of Cys183 in the NES site was proposed to retain Nrf2 in the nucleus 
[178] and Trx was reported to reduce the oxidation and promote Nrf2 nuclear exportation 
[179].  
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1.7.5.2 Nuclear Factor-κB (NF-κB)  
Activation of nuclear factor-κB (NF-κB) plays an essential role in immune response. 
Reduced key cysteines in NF-κB’s subunits are required for its DNA binding [180]. It has 
been reported that under oxidative/nitrosative stress, the activation of NF-κB was hampered 
in the nucleus [181]. Trx system exerts dual roles in regulating NF-κB. In the cytosol, 
overexpression Trx stabilizes IκB, the inhibitor of NF-κB, which sequesters NF-κB in the 
cytosol and promotes its degradation. While in the nucleus, Trx reduces the oxidized cysteine 
in NF-κB and promote the DNA binding [182].  
1.7.5.3 Redox Factor -1 (Ref-1) and Activator Protein–1(AP-1)  
AP-1 is not a single protein, but represents a group of proteins homo- or heterodimers formed 
between the proteins of the basic region-leucine zipper (bZIP) mainly from Jun, Fos, 
activating transcription factor (ATF), musculoaponeurotic fibrosarcoma (MAF) protein 
families [183]. AP-1 regulates a wide range of genes involved in cellular proliferation, 
transformation, differentiation, survival, and death. Oxidation of cysteine in DNA binding 
site of AP-1 hampers its transcriptional activity [184]. However, Trx does not directly reduce 
AP-1, the reduction requires the assistance of another redox protein, redox factor 1 (Ref-1) 
which transfers reducing power from Trx to AP-1 and restores its activity [185] (Fig.7). 
1.7.6 Trx System-mediated Reversible Thiol Modification 
1.7.6.1 S-nitrosylation 
The evolutionarily conserved active site -CXXC- motif in Trxs emphasizes its biological 
importance. Trx system has been intensively investigated for its thiol reduction activity 
during last few decades and recent studies reveal that Trx is also an efficient denitrosylase. 
During S-denitrosylation, one cysteine at active site may form intermolecular disulfide as an 
intermediate or get transnitrosylated by the substrate as an intermediate. The resulting product 
is nitroxyl (HNO) or NO and oxidized Trxs which can be reduced by TrxR [186] (Fig.6). 
Using a proteomic approach, a broad spectrum of denitrosylation substrates, including some 
nitrosylation examples we discussed above, were discovered and Trx has been suggested as 
the major denitrosylase in mammalian cells [187].  
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Fig. 6 Proposed mechanism of Trx-mediated S-denitrosylation. 
It is worth noting that hTrx1 plays different roles upon different redox status in S-
nitrosylation regulation. Besides the two cysteines at the active site, hTrx1 contains three 
structural cysteines, Cys62, Cys69 and Cys73, all of which can be nitrosylated in different 
contexts [188]. However, so far only Cys69 and Cys73 were reported being nitrosylated 
physiologically [189, 190]. Nitrosylated Trx1 serves as a transnitrosylase which can transfer 
the NO group to target proteins including caspases [191], Prx1 and so on [192]. The 
prerequisite for Trx1's transnitrosylase activity is the formation of active site disulfide or 
mutated active site cysteines [193]. Therefore under different redox contexts, Trx1 may serve 
as a denitrosylase or a transnitrosylase.  
Trx1 mediated regulation of apoptosis can be an example. Caspases are a family of proteins 
regulating apoptosis and have a critical cysteine for its function, which can be targeted for S-
nitrosylation. Reduced Trx1 and Trx2 can denitrosylate caspase-3 both in the cytosol and 
mitochondria and facilitate Fas-induced apoptosis which is important for neuronal 
development but may, on the other hand, contribute to the pathological progress of 
neurodegenerative diseases [194]. Interestingly, nitrosylated Trx1 is capable of 
transnitrosylating the catalytic cysteine of caspase-3 specifically and hampering caspase 
activity thereby protects neurons from stress-induced apoptosis [193] (Fig.7). Performing a 
mass-spectrum-based bioinformatics analysis in neuroblastoma cells, a study surprisingly 
found more than 40 proteins, which S-nitrosylation was reversibly regulated by Trx1 [192]. 
Among these targets, GAPDH S-nitrosylation is also highly related to apoptosis, indicating 
Trx1 is a sophisticated regulator in cell death.  
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Fig. 7 Thioredoxin regulated redox signaling. Trx is a redox regulator for several transcription factors 
involved in many cellular events, for example, AP-1, NF-κB, p53. Trx1 can direct prevent cell death by binding 
ASK1. Not surprisingly, TXNIP, the endogenous inhibitor of Trx1, can promote ASK1 mediated apoptosis. 
Different redox status of Trx1 exerts different effects on caspases. Reduced Trxs can denitrosylate and activate 
caspase 3 which executes apoptosis while oxidized Trx1 can be nitrosylated and subsequently trans-nitrosylate 
caspase 3 thereby curb the caspase 3-mediated apoptosis. 
1.7.6.2 S-sulfhydration 
Similar to NO, hydrogen sulfide (H2S) also targets reactive protein cysteines and forms 
persulfide bond (-SSH). This cysteine-based PTM is named S-sulfhydration, which has 
recently drawn a lot of attention for its biological functions. Compared with S-nitrosylation 
which only occurs in a small fraction of proteins, sulfhydration is a more abundant PTM that 
modifies about 10-25% of total amount of some proteins in the liver lysate, including actin, 
tubulin and GAPDH [195]. S-nitrosylation usually inhibits proteins' activity while 
sulfhydration typically enhances the reactivity of modified cysteines. For example, parkin is 
an E3 ligase protecting the brain from accumulation of undesired proteins. S-sulfhydration of 
parkin enhanced its E3 ligase activity and depleted parkin sulfhydration was detected in brain 
samples from PD patients, suggesting a beneficial effect on clearing misfolded proteins in the 
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brain [196]. H2S also boosted GSH production by enhancing the rate-limiting enzyme, γ-
glutamyl cysteine synthetase (γ-GCS) activity. Although the mechanism is not clear yet, it is 
highly possible that it is through sulfhydration [197]. Inflammatory cytokines can cause 
sulfhydration of GAPDH and enhance its binding to Siah1. The binding promoted Siah1 
activity of degrading postsynaptic density 95 (PSD95), which is an important protein for 
neuron maturation and synaptic plasticity. Exaggerated loss of PSD95 can be seen in several 
neuronal diseases such as dementia and depression [198]. 
Several studies have reported that Trx system catalyzed desulfhydration, the reversed reaction 
of sulfhydration, in different cases [199, 200]. Using different methods, Trx system has been 
suggested to regulate cellular desulfhydration globally [201, 202]. Grx system and 
thioredoxin-related protein of 14-kDa (TRP14) also showed the ability to reduce protein 
sulfhydration [203]. Our understanding about desulfhydration still remains vague and more 
effort is needed to elucidate the whole picture.  
1.8 GLUTAREDOXIN SYSTEM 
Glutaredoxin system, which is composed of glutaredoxin (Grx), glutathione reductase (GR) 
and glutathione (GSH), is another cellular disulfide reductase system existing in most of 
living organisms from prokaryotes, plants, virus, and eukaryotes [204]. It was first discovered 
by Prof. Arne Holmgren in 1976 as a reductase system for RNR in a mutant E.coli unable to 
replicate phage T7 and shown to lack Trx [205]. Purification of E.coli Grx to homogeneity 
[206, 207] demonstrated that it contained a single disulfide in its oxidized form with the 
unique sequence Cys-Pro-Tyr-Cys (CPYC) [208]. Grx also showed a strong GSH-disulfide 
transhydrogenase activity apart from its role as a GSH-dependent hydrogen donor for RNR. 
Subsequently, Grx was demonstrated in calf thymus [209] and purified to homogeneity [210]. 
GSH is the most abundant small molecular thiol, which is found as high concentration as 
millimolar range in cells and important to maintain cellular redox homeostasis [106]. GSH 
can reduce a wide range of proteins via a non-enzymatic mechanism [211]. The resulting 
glutathione disulfide (GSSG) can be recycled by GR utilizing NADPH as the electron donor 
[212] (Fig.4). Grxs were firstly considered to be exclusively reduced by GSH, later 
mammalian mitochondrial Grx was found to be reduced by mitochondrial TrxR, too [213]. 
Grxs are low-molecular-weight, versatile proteins playing roles in redox regulation, PTM 
modification, and iron metabolism. What’s more, glutathione peroxidases (GPxs) coupled 
with GSH is also regarded as one of the major antioxidant enzymes to scavenge ROS/RNS.  
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1.8.1 Glutaredoxin (Grx) 
So far, four isoforms of human Grx have been discovered. They are divided into two groups 
based on the cysteine numbers at the active site: the dithiol Grxs including Grx1 and Grx2 
with a CXXC active site motif; the monothiol Grxs including Grx3 and Grx5 with a CXXS 
active site motif [214].  
Human Grx1 with a Cys-Pro-Tyr-Cys (CPYC) active site is mainly present in the cytosol and 
functions as an antioxidant enzyme. Although the gene of Grx1 does not contain subcellular 
localization sequence, it is also distributed in the nucleus [215] [216], mitochondrial 
intermembrane space [217], and secreted into plasma [218] (Fig.8). To our surprise, knocking 
out the Grx1 gene in mice does not cause obvious abnormalities [219]. Instead, some studies 
showed a protective effect against inflammation [220], cardiovascular hypertrophy [221] or 
airway hyperresponsiveness [222]. 
Human Grx2 is encoded by one gene but exists in three different splice variants. The N-
terminus of Grx2a contains a mitochondrial targeting sequence leading it into mitochondrial 
matrix [223]. Grx2b and Grx2c are located in the cytosol but these two isoforms are 
restrictedly expressed in testes, immortalized cell lines, and tumors [224]. Different from 
Grx1, the active site of Grx2 is Cys-Ser-Tyr-Cys (CSYC) instead of CPYC (Fig.8). The 
subtle substitution renders Grx2 abilities to receive electrons from mitochondrial TrxR and 
coordinating iron-sulfur cluster [213] [225]. The iron-sulfur cluster is assembled from the 
cysteine residue in the active site of two Grx2a with GSH as a ligand [226]. Under 
oxidative/nitrosative stress, the ratio of GSH/GSSG goes down and the cluster gets degraded. 
Then Grx2 is released to participate in antioxidant processes, thus Grx2 is considered as a 
redox sensor [225]. Knocking-out Grx2 in mice leads to early-onset of age-dependent 
cataract [227], enlarged hearts and high blood pressure [228]. 
Monothiol Grxs, which contain a Cys-Gly-Phe-Ser (CGFS) motif at the active site, can be 
further categorized into two groups. Grx3 consists of an N-terminal Trx domain that lacks a 
redox active motif and two monothiol Grx domains that both harbor the CGFS active site 
motif and it is also named protein kinase C interacting cousin of thioredoxin (PICOT) [229]. 
Grx3 is located in the cytosol and important for embryonic development because genetic 
ablation of Grx3 caused embryonic death between E12.5 and E14.5 [230]. Grx3 is also an 
iron-sulfur cluster protein with a similar redox-sensor function with Grx2 [231]. Another 
human monothiol Grx, Grx5, is located in mitochondria and contains a single monothiol Grx 
domain. Grx5 is evolutionarily conserved in eukaryotes [232]. It has been reported that Grx5 
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is essential for mitochondrial iron-sulfur cluster biogenesis [233]. A clinical case that a 
patient with Grx5 deficiency suffered from anemia and blood iron overload also highlights 
the importance of Grx5 in iron metabolism [234] (Fig.8). 
1.8.2 Glutathione Reductase (GR) 
Glutathione disulfide (GSSG) is reduced back to two molecules of GSH by NADPH-
dependent glutathione reductase (GR), which is highly conserved in nature from E.coli to 
human beings. Similar to TrxR, human GR is also a homodimer arranged in a head-to-tail 
fashion. Each subunit is grouped by three parts: FAD binding domain, NADPH domain and 
interface domain and the redox active site, -Cys-Val-Asn-Val-Gly-Cys- (-CVNVGC-) lies in 
the N-terminus [235]. During the catalysis, electrons are transferred from NADPH to FAD 
and then to the active site where the reduction of GSSG happens [236]. Although only one 
gene encodes GR in mammalian cells, GR is distributed in both cytosol and mitochondria 
[237]. By reducing GSSG, GR takes part in maintaining redox balance in cells. However, 
genetic deletion of GR gene did not exhibit obvious abnormality and it is reasonable to 
speculate that other disulfide reduction system and de novo GSH synthesis may compensate 
the loss of GR activity [238]. 
1.8.3 Glutathione Peroxidases (GPxs) 
GPxs are GSH-dependent peroxidases which catalyze the reduction of H2O2 or organic 
hydroperoxides to water or to the corresponding alcohols. Eight isoforms of GPxs have been 
discovered in human cells. Five of them (human GPx1 to GPx4, and GPx6) are 
selenoproteins with a selenocysteine at their active sites, the rest three GPxs (GPx5, GPx7 
and GPx8) contain cysteine-substituted active site [239]. Selenocysteine is important for GPx 
activity because substitution of the selenocysteine to a cysteine results in an activity drop by 
two to three orders of magnitude [240]. The rate of seleno-GPxs reacting with H2O2 is higher 
than 10
7
 M
-1
s
-1
 which is similar to Prxs. Thus GPxs and Prxs are considered as the primary 
scavengers of H2O2 in mammalian cells [241]. Among the isoforms, GPx1 and GPx4 are 
most well-studied. GPx1 is a homo-tetramer which reacts mainly with H2O2 and soluble low 
molecular weight hydroperoxides. Knocking out GPx1 in mice does not cause abnormal 
phenotype but sensitizes mice to acute oxidative stress induced by toxic compounds [242]. 
GPx4, which acts as a monomer, draws a lot of efforts due to its unique ability to reduce not 
only H2O2 and hydroperoxides in general, but also a broad range of lipid peroxides such as 
phospholipid, cholesterol, cholesterolester hydroperoxides either in free form or in the 
biological membranes [243]. Systemic knockout of GPx4 gene leads to embryonic death 
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which suggests GPx4 is not a simply an antioxidant enzyme [244]. Indeed, GPx4 was found 
to play an important role in counteracting lipid peroxide-induced apoptosis [245].  
1.8.4 Grx System-mediated Redox Signaling 
Besides the role as the electron donor for RNR and other proteins, Grx system mediates redox 
signaling mainly by reversibly catalyzing protein S-glutathionylation. The reversed reaction 
of glutathionylation is named S-deglutathionylation. Although several proteins such as Trxs 
[246], PDI [247] and sulfiredoxin [248] showed their deglutathionylation activity in different 
cases, glutaredoxins are considered as the major deglutathionylases due to their high affinity 
and selectivity to glutathionylated proteins [249]. Two mechanisms have been proposed for 
Grxs-catalyzed deglutathionylation: (I) the dithiol mechanism requires both cysteines in the 
active site. At the beginning, N-terminal cysteine forms a disulfide with target protein and 
releases GSH, and then the other active site cysteine attacks and leaves deglutathionylated 
protein and an active-site-disulfide Grx which can be later reduced by GSH; (II) the 
monothiol mechanism suggests that the N-terminal cysteine first takes over the -SG group 
and leaves the reduced target protein, then the glutathionylated active site cysteine can be 
reduced by GSH or forms disulfide with the other cysteine [250] (Fig.8). Although both 
mechanisms were reported from different studies, the monothiol mechanism is considered as 
the prevalent way due to its universal recognition for glutathionylated targets [251].  
Grxs exert an important influence on redox signaling by their ability of modulation protein 
glutathionylation. For example, actin was found constitutively glutathionylated in the human 
central nervous system (CNS) [252]. Studies showed that Grx1 catalyzed deglutathionylation 
of actin is crucial for its polymerization, which is a key event for cellular dynamics and 
protects neurons from accumulating disarranged actin filament [253]. In a MPTP-induced PD 
model, up-regulation of Grx restored complex I activity most likely via deglutathionylation of 
its catalytic cysteines [254]. Studies also revealed that human mitochondrial Grx, Grx2a, 
exhibited higher affinity to glutathionylated substrates and electron donors compared to Grx1, 
suggesting its important role in regulating mitochondrial redox homeostasis by 
deglutathionylation target proteins, including complex I [249, 255]. Glutathionylation of 
active site cysteine of Prx2 was also found in Grx1 knocked-out cells treated with H2O2, 
suggesting a protective role of Grx1 in guarding Prx2's activity under oxidative stress [256]. 
Interestingly, due to the high reactivity of active site cysteine (PKa ≈ 3.5), Grxs may form a 
glutaredoxin-S-S-glutathione-disulfide anion radical (GRx-SSG
•-
) which facilitates the 
transfer of –SG group to other proteins including GAPDH and PTP1B [257]. 
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Fig.8 Cellular distribution of human Grxs and two proposed mechanisms for Grx catalyzed 
deglutathionylation. Grx1, 2b, and 2c can be found both in cytosol and nucleus, Grx3 is present in the cytosol, 
Grx2a and Grx5 are located in mitochondria. The dithiol mechanism requires both active site cysteines. During 
the reaction, N-terminal active site cysteine forms a disulfide with targeted proteins. The monothiol mechanism 
needs only the N-terminal active site cysteine, which takes over the GSH mixed disulfide from targeted proteins. 
1.9 TARGETING ANTIOXIDANT SYSTEM FOR CANCER THERAPY 
Cancer is a leading cause of mortality worldwide in both developed and developing countries. 
The initiation and development of cancer are complex progresses involving in alterations in 
many cellular aspects which characterize cancer cells with uncontrolled proliferation. 
Hallmarks of cancers were described at the beginning of 21st century [258] and the concept 
has been evolved recently that oxidative stress is included [259] [260]. Cancer cells usually 
exhibit a higher level of ROS/RNS compared to normal cells due to several reasons: (1) 
Elevated energy and material demand for proliferation make cancer cells take up much more 
glucose than normal cells and switch metabolism from oxidative phosphorylation to 
glycolysis, which is known as Warburg effect [261]. (2) Alterations in mitochondrial 
respiratory chain due to mutation lead to increased possibility of electron leakage and ROS 
formation [262]. (3) Cancer-related chronic inflammation results in excessive production of 
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nitric oxide and nitrosative stress [263]. (4) Activation of oncogenes and hypoxia-response 
mechanisms promote ROS/RNS generation [264]. Cancer cells benefit from the relatively 
high level of ROS/RNS which facilitate cancer initiation, metastasis, hypoxic adaptation, and 
angiogenesis by mediating redox signaling. 
However, playing with ROS/RNS is a tricky game. When ROS/RNS level is high enough, 
cell death pathways will be activated [264]. In order to cope with the situation, cancer cells 
have to upregulate the antioxidant systems to counteract the detrimental effect of ROS/RNS. 
For example, the elevated activity of Nrf2 and Nrf2-targeted proteins, including GPxs and 
SODs, have been found in various types of cancer [265]. Trx system in cancer cells is also 
overexpressed not only to lower the oxidative/nitrosative stress, but also to inhibit apoptosis 
pathways [266]. At the end, the elevated ROS/RNS and the exhausted antioxidant systems 
reach a vulnerable equilibrium, like an acrobat walking a tightrope, in which ROS/RNS level 
is closely under the cell death threshold. As a result, cancer cells become more sensitive to 
additional ROS/RNS challenge which normal cells can well tolerate (Fig.9). Therefore, 
inducing ROS/RNS in cancer cells by promoting oxidant production or inhibiting antioxidant 
systems gains popularity in cancer therapy [267].  
Many chemotherapeutic reagents, as well as radiotherapy, have been suggested to promote 
cancer cell death by inducing ROS production [268]. Antioxidant systems have been 
considered as cancer cells’ “Achilles' heel” because cancer cells heavily rely on the 
antioxidant systems to counteract ROS/RNS. Targeting main antioxidant enzymes also 
showed promising results for cancer treatment. Numerous TrxR inhibitors have been 
developed and many of them exhibited specific toxicity towards cancer cells [269]. 
Buthionine-[S, R]-sulfoximine (BSO) is a potent inhibitor of GCL, the rate-limiting enzyme 
in GSH synthesis. A recent study showed that inhibition of GSH synthesis by BSO and 
thioredoxin antioxidant pathways by sulfasalazine and auranofin led to a synergistic anti-
cancer effect both in vitro and in vivo, emphasizing the importance of Grx and Trx systems in 
cancer cells and promising usage as drug targets [270].  
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Fig.9 Mechanism of inducing oxidative/nitrosative stress as an anticancer strategy. Normal cells have a 
relatively low basal level of ROS and antioxidant systems. In cancer cells, ROS/RNS is elevated due to various 
reasons. At the same time, antioxidant systems in cancer cells are also upregulated to maintain a vulnerable 
equilibrium. When additional ROS/RNS is added or antioxidant system is inhibited, normal cells can tolerate it 
by upregulating antioxidant systems. While cancer cells can no longer enhance its antioxidant systems and go to 
cell death.(License for non-commercial use from  Phantom Open Emoji) 
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2 PRESENT INVESTIGATION 
2.1 AIM OF THIS THESIS 
The overall aim of this thesis is, as described in the title, to investigate the role of mammalian 
thioredoxin and glutaredoxin systems under oxidative and nitrosative stress. The effect must 
be mutual thus we will study the both sides: how Trx and Grx systems change ROS/RNS and 
how they are changed by ROS/RNS. By studying the changes, we also tried to interpret our 
results in a disease-related context in which promising therapy might be derived. 
To specify in each paper: 
Paper I 
In this study, the toxic effect of several arsenic compounds on cancer cells was investigated. 
Their effect on human Trx system and the importance of structure cysteine of Trx1 was 
elucidated. 
Paper II 
Apatone (the combination of vitamin C and vitamin K3) can cause cancer cell death by 
inducing oxidative stress and it is an anti-cancer drug under clinical trial. In this study, the 
mechanism of ROS production and how Trx and Grx systems get affected were investigated. 
Paper III 
Infection is a classical way to induce nitrosative stress due to NO produced by iNOS. In the 
paper, we studied the role of iNOS and NO during Trypanosoma brucei infection. 
Paper IV 
In this study, we investigated the role of Grxs in the regulation of NO metabolism and their 
potential usage as S-denitrosylases. 
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2.2 METHODOLOGY 
The methods used in the papers included in this thesis will be briefly described. For more 
details, please check the sections of materials and methods in each paper. 
Cell culture (Paper I-III) 
In Paper I, human neuroblastoma cell line SH-SY5Y was cultured with 1 g/L glucose 
Dulbecco's modified Eagle's medium (DMEM) containing 100 units/ml penicillin, 100 µg/ml 
streptomycin, 2 mM l-glutamine, and 10% (v/v) fetal bovine serum (FBS). In Paper II, human 
prostate cancer cell line LNCaP was cultured in RPMI 1640; human glioblastoma cell line 
A172, human prostate cancer cell line PC3, human pancreatic cancer cell line PANC-1 and 
human breast cancer cell line MCF7 were cultured in DMEM; human lung cancer cell line 
A549 was cultured in F-12 medium. All medium was supplemented with 10% FBS and 2 
mM l-glutamine. In Paper III, Bone marrow-derived macrophages from mice were cultured 
in DMEM containing glucose and supplemented with 2 mM L-glutamine, 10% FBS, 10 mM 
Hepes, 100 μg/ml streptomycin, 100 U/ml penicillin. All cell lines were kept in a humidified 
atmosphere of 5% CO2 at 37 °C. 
Cell viability assay (Paper I & II) 
MTT assay is widely used to measure cellular proliferation and viability. The principle is 
based on the reaction that MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium 
bromide) can be reduced into purple formazan by living cells. The exact cellular mechanism 
of MTT reduction has not been fully understood yet, but likely involves reaction with NADH 
or similar reducing molecules both in mitochondria and cytosol that transfer electrons to 
MTT [271].  
Cells were seeded into 96-well plates at 1x10
4
 cells per well and allowed to adhere and get 
confluent for about 24 h. The following day, cells were treated with different reagents with 
desired concentration for different time periods after which, media was carefully removed 
and replaced with 150µl fresh medium containing 0.5 mg/ml MTT. After incubating for 3 h, 
the medium was carefully removed and the formazan crystal formed was dissolved in 150 µl 
of DMSO. Absorbance at 550 nm was recorded. 
TrxR activity assay (Paper I) 
For recombinant TrxR activity, a Trx-insulin-coupled assay was employed based on the 
reaction that TrxR transfers electrons from NADPH to Trx, which then reduces insulin [272]. 
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Briefly, NADPH-reduced TrxR1 (1 μM) was incubated with arsenic compounds at room 
temperature for 60 min. Then, TrxR1 activity was assayed by insulin reduction assay in the 
solution containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 200 µM NADPH, in the 
presence of 5 μM Trx1 and 160 μM insulin. The absorbance at 340 nm was followed and 
TrxR1 activity was calculated by measuring the slope of absorbance change during the initial 
10 minutes. 
Cellular TrxR activity was measured by a fluorescent assay which is more sensitive and 
allows determine low level of TrxR in biological materials. In this assay, insulin was replaced 
by a redox-sensitive fluorescent substrate which increases fluorescence upon reduction by 
Trx. In general, 30 µg of cell lysates were used to determine TrxR activity with a Kit for 
assay of mammalian TrxR (FkTRXR-03*) from IMCO (www.imcocorp.se), which was 
optimized from previous method [273]. The cell lysates from untreated cells were used as a 
control. 
Detection redox status of Trx (Paper I & II) 
Thioredoxin redox status was detected using a modified redox western blot method [274]. To 
prepare mobility standard, cells were lysed in urea lysis buffer (8 M urea in in 50 mM Tris-
HCl, 1 mM EDTA, pH 8.0) containing DTT to denature and fully reduce proteins. Then 
lysate was aliquoted and incubated with different molar ratio of iodoacetic acid (IAA) and 
iodoacetamide (IAM). If a protein contains “n” cysteines, the reaction will create “n+1” 
isoforms labeled with different numbers of IAA or IAM. When the sample is separated in 
urea-PAGE, IAA adducts get ionized and exhibit higher mobility while the IAM adducts stay 
neutral, therefore, “n+1” bands will be shown on the gel which can be used as a standard 
(Fig.10). For samples, after treatment, cells were lysed in urea lysis buffer containing 30mM 
IAA and incubated at 37 °C for 30min to alkylate free thiols. After centrifugation, the 
supernatant containing proteins was precipitated by cold acetone: HCl (98:2, v/v). The 
precipitate was pelleted by centrifugation and washed in cold acetone: HCl for two times and 
resuspended in urea lysis buffer containing 3.5 mM DTT. After 30min incubation at 37 °C, 
10 mM IAM was added for another 30 min incubation. Protein concentration was measured. 
After separation in urea-PAGE, membranes were processed for western blot and probed 
using goat anti-Trx1 antibody. 
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Fig. 10 The principle of redox western blot for hTrx1 
Total cellular glutathionylation detection (Paper II) 
Cells were seeded into 6-well plates at 3x10
5
 cells per well. After treatment, cells were 
washed and harvested at different time points in cold PBS. Cells were lysed in lysis buffer 
(25 mM Tris·HCl, pH 7.5, 100 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 20 mM NaF, 1 
mM Na3VO4, 20 mM sodium ß-glycerophosphate, 10 mM sodium pyrophosphate, 0.5% 
Triton X-100) containing protease inhibitor cocktail (Roche) and 50 mM iodoacetamide 
(IAM). After centrifugation, 25 µg of total proteins from the supernatant were separated by 
SDS-PAGE and probed with anti-glutathione antibody (VIROGEN Corporation). Anti-
GAPDH (Santa Cruz) antibody was used as loading control.  
Biotin-switch assay (Paper III) 
Biotin-switch assay is a well-established method to detect protein S-nitrosylation. It can be 
used for comparing total cellular S-nitrosylation level, as well as fishing out individual 
proteins. The basic idea is to use ascorbate to specifically switch the unstable S-nitrosothiols 
into biotin labeled disulfides which are stable and detectable by streptavidin-biotin 
interaction. Cell lysate was prepared by adding urea lysis buffer (8 M urea, 50 mM Tris pH 
8.0, 1 mM EDTA) and 20 mM blocking reagent methyl methanethiosulfonate (MMTS). The 
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lysates were incubated at 50°C for 30 min with frequent vortexing and centrifuged at 17,000 
g for 10 min. Proteins in the supernatant were precipitated with cold acetone in order to 
remove free MMTS. The pellet was washed 3 times with cold acetone and resuspended in 
urea lysis buffer with 20 mM sodium ascorbate and 0.5 mM N-6-(biotinamido) hexyl-3'-(2'-
pyridyldithio) propionamide (Biotin-HPDP). The reaction was done at room temperature for 
1 hr. Cold acetone was then added to remove excessive biotin-HPDP and the resulting pellet 
was dissolved into 2 M urea 50 mM Tris-EDTA (pH 8.0). Protein concentration was 
determined by BCA protein assay. Protein samples (10 μg) were loaded on a SDS-PAGE, 
blotted and biotinylated proteins were detected by streptavidin-HRP. To detect NF-κB p65 
nitrosylation, biotinylated proteins were immunoprecipitated by high capacity neutravidin 
agarose resin at 4°C overnight. Proteins were eluted with 20 mM HEPES, pH 7.7, 100 mM 
NaCl, 1 mM EDTA, 100 mM DTT. Eluted proteins were loaded on a SDS-PAGE for 
detection of p65 by immunoblotting NF-κB p65 antibody. 
DAN fluorescent assay (Paper III & IV) 
The principle of this assay is based on the reaction of DAN (2,3-diaminonapthalene) with 
NO
+
 liberated from S-nitrosothiols following mercuric chloride addition to yield a primary 
nitrosamine which is converted rapidly to a fluorescent triazole, 2,3-naphthotriazole (NAT). 
DAN was dissolved in 0.62 M HCl to a concentration of 5 mM, HgCl2 5 mM was prepared in 
H2O. DAN, at a final concentration of 100 µM, and HgCl2, at a final concentration of 300 
µM were added into S-nitrosothiols samples and kept at room temperature in dark for 30 min. 
NaOH was added to a final concentration of 0.5 M to terminate the reaction [275]. The 
fluorescence of the samples was read by Perkin Elmer EnSpire 2300 multilabel reader 
(excitation at 375 nm, emission at 450 nm).  
Nitric oxide analyzer (Paper IV) 
Nitric oxide analyzer (NOA) is the regarded as the gold standard of S-nitrosothiols 
determination due to its high sensitivity. Cu
+
 catalyzed the decomposition of S-nitrosothiols 
was employed to convert S-nitrosothiols into nitric oxide and the corresponding thiols. The 
NO released was sent into the detection chamber filled with ozone, which reacts with NO. 
The reaction emits light and the chemiluminescence can be detected and quantified by the 
sensor.  
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3 SUMMARY AND DISCUSSION 
3.1 PAPER I 
Oxidation of structural cysteine residues in thioredoxin 1 by aromatic arsenicals enhances 
cancer cell cytotoxicity caused by the inhibition of thioredoxin reductase 1 
Xu Zhang, Jun Lu, Xiaoyuan Ren, Yatao Du, Yujuan Zheng, Panayiotis V. Ioannou, Arne 
Holmgren 
Free Radical Biology and Medicine 89 (2015) 192–200 
Background 
Exposure to arsenic leads to the onset of various diseases including cancer [276]. 
Paradoxically, arsenic trioxide (ATO) has been successfully used in the treatment of acute 
promyelocytic leukemia [277] and solid tumors [278]. One of the important mechanisms for 
arsenical-induced toxicity is to break the redox balance. Arsenicals can inhibit mitochondrial 
respiratory function, and increase ROS generation. Additionally, arsenicals like ATO can 
react with sulfhydryl groups, such as in GSH, or selenocysteines such as in TrxR, leading to 
the inactivation of antioxidant enzymes and cell apoptosis in cancer cells [279]. Another 
member in Trx system, Trx1, plays an important role in maintaining redox homeostasis by 
donating electrons to Prx which removes H2O2 efficiently. Although various arsenical 
compounds have been synthesized, the relationship between arsenical structure and their 
cytotoxicity is not well-studied yet. In this study, we investigated several arsenicals and their 
effects on Trx system and elucidated their different toxic mechanisms. 
Main findings 
TrxR inhibition is a mechanism of arsenical-induced cytotoxicity 
In this study, we found that 7 arsenic compounds (As1 to As7) inhibited TrxR activity both 
on pure protein level and cellular level. Cytotoxicity results revealed that the killing effect 
was highly related to their inhibitory effect on TrxR. Interestingly, As6 and As7 showed 
much higher cytotoxicity than the rest, although their ability to inhibit TrxR was not above 
the other compounds.  
Aromatic arsenical compounds highly oxidized hTrx1  
To further understand why As6 and As7 were more toxic, we studied the effects of arsenicals 
on hTrx1 itself. After incubating the arsenicals with pre-reduced hTrx1, only compounds with 
an aromatic group (As5, As6, and As7) led to the formation of hTrx1 dimer or oligomer. Free 
thiols titration showed that high concentration of As7 can oxidize all 5 cysteines while high 
  37 
concentration of As6 can maximally cause oxidation of 2 out of 5. ATO did not change the 
number of free thiol in Trx1 even at as high as 10 fold concentration of Trx1.  
Human Trxs has two cysteine residues in its active site (CGPC), which can reduce the 
disulfide of target proteins by a thiol-disulfide exchange reaction. In addition, hTrx1 contains 
three structural cysteines, Cys62, Cys69, and Cys73. These additional cysteines attract more 
and more attentions because studies have shown that the disulfide between Cys62 and Cys69 
is important for the regulation of Trx1 activity and Trx-mediated redox signaling [160] [280]. 
In order to know which 2 cysteines were affected by As6, a C62S/C73S double mutant hTrx1 
and human Trx2 were used to incubate with As6. The result indicated that Cys62 and Cys69 
were involved in the reaction.  
As6 and As7 activated Nrf-2 pathway 
Treating cells with As6 and As7, both protein and mRNA levels of cytosolic TrxR1 and Trx1 
got increased. The nuclear factor erythroid 2-related factor 2 (Nrf-2) regulated genes 
including heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) were 
dramatically increased, indicating the treatment induced ROS production and activated Nrf-2 
pathway. 
Oxidation of cysteines in hTrx1 impaired its ability to reduce Prx1 
Peroxiredoxin 1 (Prx1) removes H2O2 by receiving electrons from Trx1. Arsenicals-induced 
Trx1 oxidation may disturb the interaction between Trx1 and Prx1. We found that As7- 
treated, but not As6-treated, Trx1 lost its activity to reduce Prx1, suggesting the reducing 
ability depends on the active site cysteines. Using a TrxR and NADPH coupled assay, we 
found both As6 and As7 pretreated Trx1 failed to reduce Prx1, indicating oxidation of Cys62 
and Cys69 affected its ability to transfer electrons from TrxR and NADPH to Prx1. 
Discussion 
Cancer cells generally have elevated ROS production due to several reasons and benefit from 
the effect of H2O2 mediated signaling. Trx1 and TrxR1 have been found to be overexpressed 
in certain cancer cell lines as a strategy of counteracting the harmful effect of ROS. These 
observations suggest Trx system as an attractive target for cancer treatment. Indeed, the low 
pKa value of the selenocysteine in TrxR makes it highly reactive, and its location in the open 
C-terminal active site makes it easy to be accessed by electrophiles, including anticancer 
drugs such as cisplatin, mitomycin C, doxorubicin and so on [281]. Previous study from our 
laboratory has shown that ATO inhibited TrxR1, most likely by reacting with the selenium-
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containing active site [279]. Here we showed that the inhibition of TrxR1 is necessary for the 
cell toxicity, implying that TrxR1 is a reliable target for arsenic compounds as anticancer 
drugs. 
However, only inhibiting TrxR1 is not enough to induce cell death. It is the redox status of 
Trx1 that determines the cell fates [282]. In most cases, inhibition of TrxR1 hampers the 
reduction of its primary substrate, Trx1. Interestingly, some compounds can not only inhibit 
TrxR1 activity, but also convert the enzyme into an NADPH oxidase which produces ROS 
and causes Trx1 oxidation. This phenomenon can be usually found when the selenocysteine 
of TrxR1 is targeted by electrophiles, or the C-terminus of TrxR1 is truncated that SecTRAPs 
(selenium compromised thioredoxin reductase-derived apoptotic proteins) are formed [283]. 
In this study, although we didn’t check whether SecTRAPs were formed or not, As6 and As7 
inhibited TrxR activity, at the same time led to oxidation of Trx1. Trx1 is an important 
mediator of cell death in that it directly interacts with key proteins in cell death pathway. As 
we discussed in the introduction section, ASK1 and PTEN-mediated apoptosis are highly 
dependent on the redox status of Trx1 that oxidation of Trx1 releases ASK1, PTEN and 
activates their activity [282].  
The importance of the structural cysteines in hTrx1 was highlighted in this study. The three 
additional cysteines make hTrx1 more susceptible to oxidation. Cys73 is exposed on the 
surface of the hTrx1 structure and has been suggested to form intermolecular disulfides with 
Cys73 in another hTrx1 [284]. A second disulfide outside the active site can be formed 
between Cys62 and Cys69, and the oxidized Trx1 with two disulfides cannot be reduced by 
TrxR and NADPH [285]. However, the structural disulfide of Trx1 can be reduced by Grx 
system [286]. Cys62 and Cys69 are both partially buried under α-helix3 and not easily 
accessible, however, a recent study showing that thioredoxin can undergo a large 
conformation change to expose Cys62 and Cys69 [287], which may explain why they can be 
targeted by As6.  
Our data also showed that oxidation of Trx1 blocked electron transfer for Prx1, which is a 
key enzyme for scavenging H2O2. Prx1 contains four cysteines: active site Cys52, Cys173 for 
peroxide decomposition, and extra Cys71 and Cys83. The catalytic cycle of Prx1 involves a 
nucleophilic attack by Cys52 towards peroxide to form a sulfenic acid intermediate, which 
reacts with the resolving Cys173 in another subunit to form an intermolecular disulfide. This 
disulfide can be reduced by thioredoxin system and get reactivated [288]. Cys83 has been 
suggested to contribute to oligomer formation of Prx1 via Cys83-Cys83 bond with other Prx1 
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[289]. Here we showed that Trx1 reduce not only the intermolecular Cys52-Cys173 
disulfides, but also the Cys83-Cys83 disulfides.  
3.2 PAPER II 
Vitamin C and K3 cause cancer cell death by oxidative stress and effects on ribonucleotide 
reductase and its electron donors  
Xiaoyuan Ren, Sebastin Santhosh, Lucia Coppo, Fernando Ogata, Jun Lu and Arne 
Holmgren 
Submitted manuscript 
Background 
Apatone is an investigational drug that has been used in Phase I /II clinical trials for cancer 
treatment [290]. The drug comprises vitamin C / vitamin K3 ( 100:1) and several types of 
cancer cells have been reported to be sensitive [291]. The design rationale of the drug is 
based on the idea that cancer cells take up oxidized VC (dehydroascorbic acid) via glucose 
transporters, which are highly expressed in cancer cells, and reactive oxygen species (ROS) is 
produced via a redox cycle formed by VC and VK3[292]. Following increased oxidative 
stress, stopped cell cycle, apoptosis and autophagy have been reported [293]. However, the 
exact action mechanism of Apatone has not been fully understood yet. 
In this study, we investigated the effect of Apatone on Trx and Grx systems and their 
important downstream proteins such as RNR and GPx. We also proposed a redox-related 
mechanism for Apatone induced cell death. 
Main findings 
Apatone inhibited RNR and caused replicative stress in cancer cells 
Due to its important function in DNA replication and repair, RNR was found to be highly 
expressed in cancer cells. We found Apatone showed a synergetic inhibitory effect on 
recombinant RNR activity which is more efficient than VC or VK3 alone. The inhibitory 
effect of Apatone was partially rescued by adding catalase, suggesting Apatone acts via the 
generation of H2O2. RNR activity in cancer cells was also inhibited by Apatone treatment. 
Apatone-treated cells also showed less thymidine incorporation, suggesting they are under a 
replicative stress.  
Apatone induced Trx1 oxidation and total protein glutathionylation 
 40 
When different cancer cell lines were treated with Apatone (VC: VK3 = 500: 5 µM), A172 
cells exhibited higher sensitivity than LNCaP cells. We found that Apatone treatment induced 
a higher level of total cellular glutathionylation, higher Trx1 oxidation in A172 cells than in 
LNCaP cells. The results indicated Apatone caused higher oxidative stress in A172 which 
explained the different sensitivity. The cellular GSH content was also decrased by Apatone 
treatment. 
Apatone enhanced cellular lipid peroxidation and inhibited GPX activity 
Apatone treatment caused a higher level of lipid peroxidation in A172 cells than LNCaP cells 
in a time-dependent manner, which is consistent with the viability assay. The enhanced lipid 
peroxidation indicated an elevated ROS production and/or inhibited antioxidant system. In 
addition, Apatone inhibited GPx activity both on protein and cellular level that may also 
contributed to the elevated lipid peroxidation. 
AIF-mediated Apatone induced cell death 
Since previous studies have suggested that Apatone induced cell death is via a caspase-
independent manner [294], we studied another cell death effector that is emerging as a central 
mediator of this process, apoptosis-inducing factor (AIF). Apatone treatment promoted AIF 
nuclear translocation, especially in A172 cells which are more sensitive to Apatone. VE 
supplement hampered the nuclear translocation of AIF in A172, suggesting lipid peroxidation 
may trigger the cell death pathway. 
Discussion 
Using vitamin C as an anticancer reagent has been pioneered by Linus Pauling since 1970s 
[295]. However, the result has been contradicted by studies carried out in Mayo clinic [296, 
297]. Later studies revealed that the administration routine matters for the treatment because 
oral administration of VC can maximally reach about 200 µM in blood, while intravenous 
administration can bypass the limitation and go beyond 10 mM [298] [299]. Low 
concentration of VC in blood serves as an antioxidant while a high concentration of VC 
dramatically induces oxidative stress in cells. Apatone is another strategy to use VC at low 
concentration by redox-cycling VK3. VK3 can be reduced by VC into its semiquinone form 
that sequentially transfers electrons to O2 to generate ROS [300].  
Increasing ROS has been considered as a specific strategy for cancer treatment due to the 
reasons we have discussed in the introduction section. Moreover, another grade of specificity 
for Apatone consists in the uptake. In order to cope with the high energy demand, cancer cells 
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usually upregulate glucose transporters. Because of the structural resemblance of DHA to 
glucose, Apatone can be rapidly taken up by glucose transporters that are overexpressed in 
tumor cells [301]. 
It is worth noting that the two major antioxidant systems, Trx and GSH systems, were 
affected by Apatone treatment. The consequence was not only diminished antioxidant 
capacity, but also dysregulated downstream proteins. RNR, which receives electrons from 
Trx and Grx, got affected not only by the limited electron supply, but also by Apatone itself. 
RNR is essential for cancer cells to maintain dNTP homeostasis for DNA replication and 
repair. The dual inhibitory effect of RNR led to replicative stress in cancer cells. Apatone-
induced lipid peroxidation can also be explained by multiple reasons: (1) oxidized Trx can 
not reduce Prx and led to accumulation of H2O2 which oxidized lipid; (2) GPx activity was 
directly inhibited by Apatone; (3) decreased GSH content limited GPx activity.  
Our study is the first time to link Apatone’s killing effects to a caspase-independent cell death 
pathway, AIF. AIF is a conserved mitochondrial flavoprotein mediating cell death upon the 
apoptotic stimulus. During the AIF-mediate cell death, it translocates from mitochondria into 
the nucleus to trigger chromatin condensation and DNA degradation [302]. Studies have 
shown that lipid peroxide triggered the AIF-induced cell death [303] which is consistent with 
our results that showed a correlation between elevated lipid peroxidation and increased AIF 
nuclear translocation. What’s more, Trx1 was found to bind AIF in cytosol under 
physiological condition [304] and oxidation of Trx1 also contributed to cytosolic release and 
nuclear accumulation of AIF.  
3.3 PAPER III 
Nitric Oxide Protects against Infection-Induced Neuroinflammation by Preserving the 
Stability of the Blood-Brain Barrier 
Gabriela C. Olivera, Xiaoyuan Ren, Suman K. Vodnala, Jun Lu, Lucia Coppo, Chaniya 
Leepiyasakulchai, Arne Holmgren, Krister Kristensson, Martin E. Rottenberg 
PLoS Pathog. 2016 Feb; 12(2): e1005442. 
Background  
Infection of parasite Trypanosoma brucei (T.b.) causes human and animal African 
trypanosomiasis. During the early stage of infection, the parasites overrun the hemolymphatic 
system, while during the late meningo-encephalitic stage severe signs of nervous system 
involvement are observed [305]. Infection-induced NO production by iNOS is a host 
defending mechanism mediated by macrophages. Meanwhile, overexpression of NO has been 
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considered as a risk factor for neuroinflammation. The paradoxical effects make the function 
of iNOS and derived NO during infection-induced brain inflammation ambiguous. In this 
study, we used an iNOS knockout mouse model and infected it with T.b. to see the effect of 
NO during parasite infection and brain inflammation.  
Main findings 
iNOS-derived NO impedes trypanosome and T cell brain invasion by maintaining the 
integrity of blood-brain-barrier (BBB) 
After 15 days of parasitic infection, wild-type (WT) and iNOS knockout (KO) mice showed a 
similar level of parasitemia. However, more parasites and T cells were found in KO mice 
brains than those in WT’s. The infected KO mice also showed higher BBB permeability than 
infected WT mice which was proven by IgG and Evans blue and explained the difference in 
the parasite and immune cell invasion.  
Infection with T.b. brucei stimulates the expression of iNOS in macrophages 
Parasites infection significantly increased iNOS mRNA level which led to higher protein 
nitrosylation level in serum and brain in WT mice than in KO mice. Treating KO mice with 
S-nitrosoglutathione (GSNO), a NO donor, lowered the number of parasites passing through 
the BBB, suggesting a beneficial role of NO in keeping BBB stability. Since iNOS is mainly 
expressed by both macrophages and glial cells, flow cytometry was used to identify which 
type of cells contributed most to the NO production. CD45
high
CD11b
high
 inflammatory cells, 
which were characterized as inflammatory monocytes and macrophages, were observed in 
brain cell suspensions from infected mice. Although microglial cells got activated after 
infection, no increased iNOS expression was detected. These results were also confirmed by 
immunostaining that macrophages in the brain are the main source of NO during T.b. 
infection. 
iNOS-derived NO mediates the protection by S-nitrosylating p65 subunit of NF-κB 
The mechanism of iNOS-mediated BBB protection was studied. Brains from infected mice 
had higher tnf mRNA level than uninfected controls, especially in infected KO mice which 
are twice higher than infected WT mice. After GSNO treatment, tnf mRNA level was 
significantly reduced in infected KO mice. We used LPS treated bone marrow-derived 
macrophages (BMM) as an in vitro model and similar results were obtained. NF-κB plays a 
central role in immune response and mediates the expression of iNOS and various cytokines 
including TNF-α. LPS treatment increased nuclear translocation of NF-κB and GSNO 
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treatment impaired the effect. What’s more, increased level of nitrosylated p65 subunit of 
NF-κB was observed in LPS treated WT BMM and WT infected mice brains but not in KO 
ones. Therefore, NO exerts its neuronal protection via hampering NF-κB’s nuclear 
translocation and activation by S-nitrosylating its p65 subunit. 
MMP9 mediates parasite and T cell penetration and BBB leakage 
TNF-mediated activation of matrix metalloproteases (MMPs) is critical for BBB disruption 
due to their ability to degrade matrix proteins. We found significantly higher mRNA 
expression of MMP9 in the brains and in the macrophages from infected mice. The 
expression of MMP9 was TNF-dependent and increased in the absence of iNOS. 
T cells are required for iNOS-mediated protection during infection 
Whether T cells also played a role in the iNOS-mediated inhibition of parasite penetration 
into the brain was then studied. B and T cell deficient rag1
-/- 
and rag1
-/-
/inos
-/-
 mice showed 
similar parasitemia levels and very few parasites in the brain parenchyma after infection, 
indicating that T and/ or B cells are required for the increased parasite penetration into the 
brain of inos
-/-
 mice. When infected rag1
-/-
 mice were transferred with T cells, the parasite 
density in the brain increased. Tnf, inos and ifng mRNA levels were all elevated in the brains 
of infected rag1
-/- 
mice transferred with T cells compared to non-transferred infected controls. 
High levels of ifng mRNA were found in T cell-enriched populations from brains of infected 
mice but not in macrophages or microglia. Thus, T cells express IFN-γ in the brain and 
contribute to the induction of TNF-α and iNOS expression by brain macrophages. In 
summary, both TNF-α and activated T cells are necessary to stimulate iNOS expression by 
brain macrophages, while reciprocally iNOS-derived NO dampens the TNF-α and T cell-
mediated brain invasion of parasites and leukocytes. 
Discussion 
NO production is a commonly used mechanism for the host to defend invading microbes, 
such as virus, bacteria, and parasites. However, the role of NO during African 
trypanosomiasis is controversial. One study on a T. congolense model indicated that TNF-α 
and NO had a protective role in controlling parasitemia [306]. While in a T.b. model, iNOS-
derived NO suppressed bone marrow proliferation and induced anaemia [307]. Others have 
shown that the NO synthesized in T.b.-infected mice lacked trypanocidal activity in vivo 
[308]. Although there is a consensus that NO generation is stimulated by infection, the role of 
iNOS-generated NO during the infection and specifically in the brain at the encephalitic stage 
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is still unclear. In this study, we did not see the obvious killing effect of NO on parasites, but 
a protective mechanism of NO via maintaining the integrity of BBB and preventing brain 
from parasites and immune cells invasion was elucidated. 
Although several types of neuronal cells including perivascular macrophages, microglia, 
astrocytes and even neurons can produce NO, we found that in the brain parenchyma, iNOS 
was prominently expressed in perivascular macrophages during trypanosome infection. The 
produced NO not only S-nitrosylated proteins intracellularly, but also elevated global protein 
S-nitrosylation and nitrite/nitrate concentration in serum. T cell also participates in the 
process by producing INF-γ which is indispensable for TNF-α production. 
Consistent with our observations, a recent study also showed a beneficial effect of NO donors 
on reducing neuroinflammation and increasing cerebrovascular flow [309]. By S-
nitrosylating NF-κB, NO serves as a negative feedback to curb the inflammation. Both S-
nitrosylation of p50 and p65 subunits of NF-κB have been observed previously and S-
nitrosylation inhibited DNA binding activity of NF-κB [310, 311]. Our experiments indicated 
that NO mediates S-nitrosylation and inhibits NF-κB p65 activation in the brain of infected 
mice. The regulation of NF-κB is complicated. It is sequestered in the cytoplasm by 
inhibitory IκB (inhibitor of NF-κB) which can be phosphorylated by IκB-kinase complex 
(IKKα, IKKβ, and IKKγ) upon stimuli and get degraded by the ubiquitin proteasome. The 
degradation of IκB releases NF-κB and allows its nuclear translocation [312]. Therefore, our 
study does not exclude the possibility that NO interacts with other molecules regulating NF-
κB activation. 
We also identified MMP9 as the executor of degrading BBB integrity. MMP is a family of 
structurally related zinc-dependent endopeptidases capable of degrading extracellular matrix 
(ECM) and basement membrane, both in physiological and pathological events. We found 
here that expression of MMP9 in the brains of infected mice in vivo and in macrophage 
cultures in vitro was dependent on TNF-α and increased in the absence of iNOS. The effect 
of NO on MMP9 has been investigated by different studies, but the data still seem complex 
and sometimes contradictory [313]. In our case, NO indirectly down-regulated MMP9 
expression by negatively regulating TNF.  
3.4 PAPER IV 
Characterization of mammalian glutaredoxin isoforms as S-denitrosylases 
Xiaoyuan Ren, Rajib Sengupta, Jun Lu, Jon O. Lundberg, Arne Holmgren  
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Submitted manuscript 
Background 
Protein S-nitrosylation is a reversible PTM. Under physiological condition, the homeostasis 
of S-nitrosothiols is kept in a balance between S-nitrosylation and S-denitrosylation. 
Although several proteins including GSNOR, PDI and Trx, have been identified as S-
denitrosylases, there still remains a lot unknown in S-denitrosylation and the role of Grx 
system in regulating NO metabolism has never been investigated. In this study, we 
characterized Grxs as S-denitrosylases. 
Main findings 
Reduced human Grx1&2 denitrosylates S-nitrosothiols 
Reduced human Grx1 and Grx2a exhibited denitrosylase activity towards L-Cys-SNO, 
GNSO and HEK cell-derived S-nitrosylated proteins (HEK-PSNOs). The denitrosylase 
activity is highly related to their redox status. If one cysteine at the active site of Grx1 was 
mutated (C26S), it lost denitrosylase activity, suggesting the importance of active cysteine for 
the catalysis. In addition, we found a subgroup of HEK-PSNOs remains in the presence of 
high concentration of GSH. When Grx1 was added, those GSH-stable HEK-PSNOs were 
further denitrosylated.  We also identified caspase 3 and cathepsin B as two substrates for 
Grx1-mediated denitrosylation.  
Monothiol Grxs denitrosylates HEK-PSNOs 
Monothiol Grxs can deglutathionylate protein mixed disulfide via the monothiol mechanism. 
In this study, we investigated whether monothiol Grxs can mediate S-denitrosylation using an 
active site C40S mutant human Grx2a and a naturally occurred human Grx5. Monothiol Grxs 
alone did not show any denitrosylation activity, however, when they were coupled with GSH, 
those GSH-stable HEK-PSNOs got further denitrosylated. Thus, GSH and Grxs have a 
cooperative effect on denitrosylating proteins. 
Crosstalk between Grx and Trx in denitrosylation  
Both Trxs and Grxs contain structural cysteines which can be nitrosylated in different 
biological conditions. Nitrosylated Trx1 (Trx1-SNO) at Cys73 serves as a transnitrosylase 
which transfers the NO group to target proteins including caspases [191], peroxiredoxin 1 
(Prx1) etc. [192]. Therefore understanding how Trx1-SNO is regulated is of high importance. 
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We found that denitrosylation of Trx1-SNO by GSH was facilitated by monothiol Grx2a, but 
not by Grx1. Trx system failed to denitrosylate Grx1-SNO 
Discussion 
This study is the first time to reveal the role of Grxs in S-denitrosylation. We found that 
human dithiol Grxs directly denitrosylated L-Cys-SNO and GSNO, which are the two most 
common cellular low molecular weight SNOs in living organisms and have been used as NO 
donors in various studies. GSNO can slowly release NO extracellularly. L-Cys-SNO is a 
more potent trans-nitrosylation reagent which is imported by the amino acid transporter 
system L into cells and performs protein S-nitrosylation [314]. 
GSH, as an essential member in Grx system at high biological concentration, has been shown 
to catalyze protein denitrosylation in different biological events [315, 316]. We also found 
that HEK cells pretreated with BSO, a compound inhibits GSH production, were more 
susceptible to NO donor-induced cell death (data not shown). Even though, we found that 
there are some proteins resistant to the denitrosylation effect of GSH. When Grxs were 
added, those GSH-stable nitrosylated proteins were further denitrosylated. This result 
indicated an indispensable role of Grxs in S-denitrosylation. 
S-nitrosylated caspase 3 was identified as one of the stable S-nitrosothiols in the presence of 
GSH and has been reported to be specifically denitrosylated by the Trx system [191]. Here 
we found that reduced Grx1 can also denitrosylate caspase 3. The denitrosylation of the 
functional cysteine in cathepsin B could also be mediated by Grx1. Since both caspase 3 and 
cathepsin B play important roles in apoptosis, our results indicate a possible function of Grx1 
in the regulation of apoptosis through its denitrosylase activity. 
Grxs are considered as the major deglutathionylases due to their high affinity and selectivity 
to glutathionylated proteins [249]. Two mechanisms have been proposed: the dithiol and the 
monothiol mechanisms. In this study, we also noticed that coupled with GSH, both dithiol 
Grxs and monothiol Grxs can denitrosylate HEK-PSNOs, suggesting that Grxs-mediated 
denitrosylation can be via both mechanisms similar to Grx-mediated deglutathionylation. In 
addition, monothiol Grxs exhibited a broader substrate than dithiol Grxs in denitrosylation. 
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4 CONCLUSION AND FUTURE PERSPECTIVES 
This thesis further explored the interaction between ROS/RNS and the two major antioxidant 
systems, Trx and Grx systems, under different conditions. The findings of the thesis added a 
small piece to the big complex picture of redox regulation and may inspire others for future 
studies, because it is evident that ROS/RNS play essential roles in both physiological and 
pathological conditions. 
In Paper I, arsenicals-induced cytotoxicity was linked to the Trx system. Interestingly, 
different arsenic compounds exert their toxicity via different mechanisms. Even so, inhibition 
of TrxR emerges as a universal basis for arsenical-induced cytotoxicity. Arsenic compounds 
with aromatic groups exhibited higher toxicity due to their ability to oxidize Trx1 besides the 
inhibitory effect on TrxR. The importance of the structural cysteines of Trx1 was also 
highlighted that formation of Cys62-Cys69 disulfide hampers electron transfer from TrxR. 
Structure modeling suggested that Cys62-Cys69 disulfide substantially alters the structure in 
this region proximal to the active site [285], that might explain the loss of ability to receive 
electrons from TrxR. However, the crystal structure is needed to confirm the speculation. The 
arsenicals used in this study provide us a handy toolkit to investigate certain cysteine 
functions by specifically oxidize desired cysteines into disulfide. What’s more, Grx system 
has been reported by our lab to serve as a backup of TrxR to reduce Trx1 [160, 317], and 
whether Grx system is also affected by arsenicals should be addressed. Arsenicals treatment 
has gained some success in treating leukemia, our study may help to elucidate the action 
mechanism and develop strategy to minimize side effect. Another aspect need to be 
considered is the physiological role of Cys62-Cys69 disulfide. Although a previous study 
from our lab has shown that treating A549 cells with high concentration of H2O2 can induce 
double disulfides formation in Trx1 [160], there is concern that whether it can happen in 
physiological condition. There might be a possibility that H2O2 generated by NOX during 
certain processes may reach such a high local concentration which will trigger the redox-
dependent signaling pathways. Because Prxs receive reducing power from Trx1 to efficiently 
remove H2O2, Cys62-Cys69 disulfide blocks electron flow from TrxR to Prx via Trx1 and 
allows H2O2 accumulation. Interestingly, using pure protein, the H2O2 mediated Trx1 
oxidation was accelerated in the presence of Prx [160], suggesting a dual role of Prx in redox 
signaling. However, more evidence is needed to confirm our hypothesis.   
In Paper II, the effect of an anticancer drug, Apatone, on both systems was investigated. The 
H2O2 produced by Apatone (VC and VK3 redox cycling) dramatically disturbed the redox 
balance in cancer cells, including GSH depletion, protein hyper-glutathionylation, Trx1 
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oxidation and lipid peroxidation. RNR was also inhibited by Apatone which sequentially 
induced replicative stress in cancer cells. The mechanism of RNR inhibition by Apatone is 
unknown yet. One possible reason is that R2 subunit contains iron metal at the radical 
generation site, the chemical property of this transition metal makes R2 sensitive to redox 
turbulence. Apatone induced cell death was named autoschizis, which is characterized by 
nuclear changes, chromatin disassembly, DNA condensation and fragmentation, and 
decreased nuclear volume [318]. This phenomenon has only been described morphologically 
under microscopy, the evidence link between autoschizis and replicative stress and RNR has 
not been chained yet. We also noticed that different cell lines exhibited different sensitivity 
towards Apatone treatment. The reason behind this observation needs to be explained. Is that 
due to different basal ROS and antioxidant level, or due to different GLUTs expression level 
so cell lines with higher GLUTs can take up more Apatone than others? Understanding these 
questions will provide us knowledge about the Apatoen’s mechanism which will definitely 
help us to select the most suitable patients and minimize side effect for clinical trials. In 
addition, a biomarker shall also be developed to monitor the patient’s response to Apatone.  
In Paper III, we elucidate a protective mechanism that iNOS-derived NO maintains the 
integrity of BBB by S-nitrosylation of NF-κB during T. brucei infection. NO serves as an 
indispensable negative feedback to curb the TNF-α–mediated neuroinflammation. The role of 
NO in neuroinflammation has been contradicted by several studies due to a fact that NO is a 
used as a weapon to fight against invading microbes, therefore, it might cause damage to host 
cells, too. Our data also showed that T.brucei and several mammalian cells exhibited similar 
IC50 to NO donors in vitro. How to utilize the beneficial effect and avoid the detrimental 
effect of NO will be an interesting topic to study. Besides the endogenous production by 
NOSs, NO can be generated by nitrate-nitrite-NO pathway [48] which provides us a possible 
way to manipulate NO production by oral administration of nitrate-rich diet. Whether such a 
diet has similar protection is still a question mark. Another concern is that whether the 
protective effect is commonly found in other brain infection diseases, such as cerebral 
malaria, viral and bacterial encephalitis, and it will be interesting to use the iNOS knockout 
mice to check other infections. The role of Trx and Grx systems was not studied in this paper; 
however, as denitrosylases they might be involved in the process and it has been reported that 
Trx1 regulates NF-κB by S-denitrosylation [319]. This study inspires us another way to 
maintain the S-nitrosylation of NF-κB: to inhibit TrxR. TrxR inhibitors have been widely 
investigated as a potential treatment for cancer [320] and they may also inhibit S-
denitrosylation by limiting Trx1 reduction via TrxR. From parasites’ point of view, NO 
produced by macrophages may also nitrosylate some of their proteins and they must be 
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equipped with mechanisms neutralizing the effect of NO to penetrate BBB anyway because 
T.brucei were also found in the brains of wild-type mice. Indeed, different from mammalian 
cells, the main antioxidant system in trypanosomes is the trypanothione system, which is 
similar to the Grx system. Trypanothione is a parasitic special form of GSH, which contains 
two molecules of GSH linked by a spermidine linker. Trypanothione reduces tryparedoxin, 
which sequentially supplies electrons to tryparedoxin peroxidase, an enzyme decomposes 
H2O2 in parasites. After the redox reaction, oxidized trypanothione is reduced by 
trypanothione reductase [321]. It will be interesting to fish out which transcription factors in 
T.brucei get nitrosylated and to investigate the role of trypanothione in NO metabolism.  
In Paper IV, we characterized Grxs as S-denitrosylases working via both dithiol and 
monothiol mechanisms. A major challenge for future study is to identify the specific 
denitrosylation substrates of Grxs. Within cells, Grxs must compete with other denitrosylases 
such as Trxs, GSNOR, PDI and so on. A Grx1-deficient model will help a lot to evaluate the 
importance of Grx1 in cellular denitrosylation. What’s more, GSH also denitrosylate many 
proteins, which makes the whole picture even more complicated. Recently, a trapping method 
was described to identify specific denitrosylation substrates of Trx1 based on the catalytic 
mechanism. In general, the C-terminal active site cysteine (Cys35) of Trx1 was mutated to 
serine. During the denitrosylation, N-terminal active site cysteine attacks the sulfur atom on 
the SNO moiety of the substrate protein. Due to the lacking of resolving cysteine, the 
substrates will be trapped by the mutant [322]. A modified method using a Grx mutant may 
also help discover the specific substrates for Grx. We have discussed that the structural 
cysteines of Trx1 can be nitrosylated and act as transnitrosylase which transfers the NO 
moiety to other proteins, for example, caspases [323]. The nitrosylation of Grx1’s structural 
cysteines was also observed [280]. It will be interesting to exam whether nitrosylated 
structural cysteines in Grx1 can transnitrosylate other proteins.   
To summarize, this thesis investigated Trx system and Grx system under oxidative and 
nitrosative stress. We found both systems are important for ROS/RNS defending, cellular 
detoxification and redox signaling.   
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